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Preface
As the costs and resources of delivering health services have increased over the years, 
the importance of evaluating in the health sector has become essential. Evaluation 
includes assessing health services, interventions, and burden of disease comprising 
the measurement of death, disability, and loss of health due to diseases, injuries, and 
risk factors.
An evaluation provides a systematic process of assessing the efficacy and  efficiency 
of health services, including an assessment of their impact on beneficiaries, whether 
it be individuals or communities. The methods of evaluating health services and 
disease burden, including data collection and analysis, have evolved in line with the 
complexity of delivering health care and health interventions. The rich picture that 
different evaluation methods derive has become critical in informing stakeholders 
and policy makers about the value of a particular program or intervention. Evaluation 
allows the improvement of disease prevention, control of disease outbreaks, and 
helps in addressing health inequities.
In this book, various evaluation studies are detailed, providing an excellent resource 
for both evaluation practitioners and academics alike. The book mainly focuses 
on exemplifying how and where evaluation is used rather than the methodology 
as such. However, a collection of economic evaluation focused chapters presents 
a comprehensive resource for readers who are interested in this area. Added to 
this is a discussion of novel evaluation approaches that can be used to assess the 
quality of programs, and burden of diseases. The evaluation of burden of disease 
is taken in a broad perspective so that different analyses are described in this book. 
The contributions go from estimating the cost of illness in Korea, the burden of 
morbidity in India, to the cost of malaria and cholera outbreaks in Mozambique.
The geographical range and variety of case studies showcase how evaluation has 
become integral for health service planning and assessment and assists public 
health policy makers to decide how to use limited resources to minimize burden and 
inequity. This book will act as a ready resource for both experienced workers and 






















While health services intend to address the healthcare needs of their respective 
populations, many a time, they are unclear as to how to expend their resources to 
attain optimal outcomes [1]. In times of financial constraints and increasing burden 
of chronic diseases, it is essential to maximise available resources to ensure sustain-
able healthcare delivery [2]. As funds will always be scarce in relation to growing 
need, appropriate choices have to be made [3]. Decision-makers need to prioritise 
resources for options that derive maximum benefit—public health or economic. 
With the growth of health service data based on technological improvements in col-
lecting data, availability of information to make these choices has not been an issue 
[1]. It is rather the need for an appropriate framework, which can guide decision-
makers as to what needs to be prioritised. In this regard, evaluation, in particular, 
evaluation of health outcomes, as a framework has been shown to be useful to guide 
appropriate health service planning and implementation [1, 4, 5].
2. Evaluation
Program evaluation has been described as a systematic process that exam-
ines the value of a program or project in light of its efficiency, effectiveness and 
appropriateness [4]. Appropriate evaluation supports accountability and enables a 
robust evidence base to guide health service planning and delivery. While there are 
various forms of evaluation approaches, commonly, many of these approaches fit 
under formative, process and summative types depending on the implementation 
phase. Evaluators need to consider the context of the program they are assessing, 
stakeholder needs and the resources available and use discretion to choose the type 
of evaluation approach [5]. In instances, where there is not enough clarity about 
the link between the interventions and outcomes, other parameters such as appro-
priateness and progress of the intervention can be considered in the evaluation 
process [1].
A type of evaluation termed economic evaluation is increasingly becoming 
popular. It is a technique initially developed by economists but now widely adopted 
by other practitioners too [3]. Basically, it compares the benefits and costs associ-
ated with an intervention and informs options that could be adopted. While there 
are various forms of economic evaluation including cost-effectiveness analysis, 
cost-utility analysis and cost-minimisation analysis, the ‘cost-benefit’ framework 
is common to all these forms [3]. Economic evaluation, however, assesses only one 
aspect of a healthcare intervention and should be complemented by other forms of 
assessment including clinical evaluation. Ideally, economic evaluation should be 
supported by clinical trials, so appropriate data can inform decision-making.
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3. Innovative approaches
Many evaluation types being used to assess healthcare interventions have been 
in use for many years. However, this does not mean they are appropriate for all the 
healthcare interventions or programs they are assessing [6]. There may be in certain 
instances requirement of customised evaluation approaches. One such innovative 
model is the integrated model of evaluation (IMoE) [6]. This model is a hybrid 
of traditional evaluation approaches that focus on before-after and input-output 
aspects of programs and theory-driven evaluation approaches that consider the 
context in which the program operates and formulates a program theory as to how 
the intervention leads to anticipated outcomes. While considering both approaches, 
it also presents a more practical version by utilising realistic elements that can be 
pursued in a timely manner. Besides, the model aligns with the health program 
context by measuring quality improvement and change that are critical to many 
health interventions [6]. The key components of the IMoE are outlined in Figure 1 
and described below.
a. Program theory is a causal statement of how the program outcomes are to 
be achieved as a result of the program intervention in the relevant context 
presented.
b. Intervention comprises the resources and inputs being introduced through the 
program or project.
c. Change considers the variations that emerge as a result of the intervention.
d. Outcomes relate to the program objectives or results.
The IMoE implementation approach involves formulating a preliminary pro-
gram theory and then testing it through collection and analysis of data [6]. The 
model is a neutral method and favours ways that are appropriate to the context 
and objectives being assessed. This approach allows for before-after intervention 
assessment but with a robust theoretical underpinning. Further, the evaluation of 
Figure 1. 
Integrated model of evaluation. Source: Reddy et al. [6].
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change that has occurred provides a comprehensive picture of the effects of the 
intervention. Thus, the hybrid approach of the IMoE enables stakeholders to gain 
more value from commissioning evaluation than relying either on traditional or 
theory-driven approaches alone.
4. Conclusion
In an era of scarce resources, budgetary pressures and increasing burden of 
diseases, it is crucial that stakeholders plan and implement healthcare programs 
appropriately [2, 3]. Evaluation is not just for assessment of the efficacy of an inter-
vention or program; it can be used to guide planning too [1, 6]. Appropriate forms 
of evaluation can benefit not only the funders but also the community by ensuring 
the sustainability of health programs and realisation of better outcomes.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Abstract
Since 2011, an international group of health policy experts has been working 
on a value-framework to be used for pharmaceutical policy decisions based on 
multicriteria decision analysis (MCDA). This tool can be easily adapted to a local 
decision-making context through a facilitated workshop format. Several workshops 
have been conducted in emerging markets to test the acceptance and feasibility of 
using MCDA in local decision-making. In China, national policy goals for expand-
ing health-care coverage pressure the provincial governments to implement more 
comprehensive coverage schemes. This chapter demonstrates the adaptation of 
a global value-framework to the local policy environment. In September 2018, 
nine leaders from provincial health insurance bureaus responsible for the urban 
employee basic medical insurance (UEBMI) participated in a 1-day workshop to 
build a consensus on the most important objectives for the health-care reform and 
to translate these into measurable criteria. The participants ranked the criteria by 
importance and MCDA methodology was used for weighing the importance of each 
criterion in the final decision. The model driving this process will be presented and 
discussed by comparing two policy options for health-care reform.
Keywords: China, multicriteria decision analysis, MCDA, insurance policy,  
decision-making, stakeholder engagement, medical savings account
1. Introduction
1.1 Provincial insurance schemes in China
In 1998, the State Council of China issued a decision on establishing the basic 
medical insurance system for urban employees [1].
As a consequence, a universal medical insurance system (UMIS) was designed 
to improve access to medical services and reduce out-of-pocket (OOP) costs for all 
Chinese citizens [2]. By 2014, 97.5% of the population had some form of insur-
ance coverage. The key options are the urban employee basic medical insurance 
(UEBMI), the new rural cooperative medical scheme (NRCMS), or the urban 
resident basic medical insurance (URBMI). The differences are in the type of 
population covered (e.g., in 2014, 283.3 million urban employees, 736 million rural 
citizens, or 314.5 million urban residents), in the annual premium per capita  
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(in 2014, 2841 RMB for UEBMI, 411 RMB for NRCMS, or 409 RMB for URBMI) 
and consequently, the scope of available funds and coverage [2].
All employing units (employers) and their employees in cities and towns are 
intended to participate in the UEBMI. The expenses of basic medical insurance shall 
be shared by employers and employees. The basic system includes the combination 
of social coordination funds and individual medical saving accounts (MSAs).
The basic medical insurance premiums are paid by individual employees with a 
2% payroll tax and by employers with 6% payroll tax. About 30% of the contribu-
tions of employers are paid into the personal MSAs, while the remaining 70% of the 
basic medical insurance premiums are collected as coordination funds. Individual 
MSAs are used for outpatient payment, the coordination funds are used for hospi-
talization and to provide for coverage of some special diseases with high medical 
costs in outpatient departments [3]. The maximum ceiling payment is limited at 
four to six times the average annual wage of local employees. The excess cost can 
be insured by commercial medical insurance or government medical assistance. In 
2010, these basic medical insurance principles were included in the Social Insurance 
Law of the People’s Republic of China [4].
1.2 Why is change needed?
Although all provinces have implemented provincial solutions for the basic medi-
cal insurance for employees, a few shortcomings have been observed over the years. 
These include the risk that the funds in the MSAs are not always used efficiently and 
may not suffice to cover a comprehensive outpatient care. In consequence, patients 
may prefer to use inpatient care facilities, which however, lead to higher overall 
costs [3, 5]. Simply put, individual choices on use of health-care funds are done with 
the short-term individual or family advantage in mind, whereas with pooled HC 
funds, decisions can be made based on overall health outcome of the population, 
and supply cost can be negotiated or managed accordingly. Not every individual 
owner of an MSA has the capability to invest in that HC service, which maximizes 
health outcomes with the available funds, and there is a risk that individual choices 
favor delayed treatments at more advanced stages of disease and to worse outcomes. 
An international study on the efficiency of MSA across different countries (China, 
Singapore, South Africa, and the United States of America) concluded that “the 
available evidence suggests that MSA schemes have generally been inefficient and 
inequitable and have not provided adequate financial protection” [6].
In addition, many healthy people or high-income employees do not use the 
savings in the personal accounts and therefore, they accumulate over time in 
the personal MSAs and are not available for the financing of current health-care 
services [7]. For example, in the Liaoning Province, the recent average proportion 
of health-care funds accumulated in individual accounts reached 40%, resulting 
in almost half of medical insurance funds being accumulated as surplus held in 
the MSAs. The same situation as was observed in Shanghai in 2015, with 40.3% of 
premium surplus accumulated in medical savings accounts [8]. In a model with a 
pooled fund administered across the whole membership, the entire budget could be 
allocated for health-care services across the members as needed. Thus, at any time, 
the money which is not spent by healthy people can be used for the treatment of 
sick people.
In terms of equity, a high variation in scope of coverage is also observed [9]. For 
access to medicines, distorted funding mechanisms create financial barriers for 
access to medicine in China [10, 11]. Research in 2014 on the impact of the UEBMI 
on equity revealed improved equity for inpatient services, but inequity growth for 
outpatient services [12].
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Affordability of medicines, a major part of outpatient care, is also still of 
concern [13]. There is a high regional variability in the scope of coverage and 
reimbursement methods [13]. For example, in some cities, the coverage for phar-
maceuticals lies within the general outpatient coverage scheme; in others a range of 
“regulated diseases” are defined for coverage, whereas in other cities, a secondary 
drug reimbursement lists exist.
Due to these challenges and shortcomings, provincial insurance authorities 
want to improve their insurance policies for UEBMI by raising reimbursement for 
outpatient care services and products. This will in turn improve utilization of all 
available funds to increase the overall efficiency of healthcare.
1.3 A format to facilitate policy decisions
In China, the responsibility for transferring nationally formulated policy objec-
tives into the provinces is decentralized and lies with the provincial administration. 
There are many options on how the provincial policies can be formulated and 
applied. Alignment of the overall central policy is important to ensure consistency 
and equity in health-care access for the Chinese population. However, new policies 
are in the responsibility of the provincial insurance authorities, and therefore, the 
policy decision has to be made in each province under consideration of the national 
policy priorities and the provincial political and health-care context. In such 
complex situations, decision support tools may help the provincial authorities to 
prioritize possible insurance options.
Among the plethora of decision support tools, multiple criteria decision 
analysis (MCDA) was chosen because this method can help to assess multiple, 
and sometimes conflicting, criteria to evaluate alternatives [14–16]. It originates 
from operational research supporting single decision-makers [17] but is increas-
ingly also used to structure decision alternatives, to prognose their consequences, 
and to facilitate dialog on the benefits and harms of decisions in a multistake-
holder context in order to enhance procedural quality in the decision-making 
process [18]. MCDA methods are used across many branches of science and 
policy-making including environmental, infrastructural, and health-care poli-
cies, prioritization, and planning [15, 19, 20].
Next to MCDA, other methods are existing to inform strategic decisions between 
alternative option and much can be learned from the world of business manage-
ment [21]. Some of these lead to increasing complexity such as strategic options 
development and analysis (SODA), a comprehensive cognitive mapping of indi-
vidual stakeholder views. Others, such as a “strengths, weakness, opportunity, and 
threat” (SWOT) analysis, structure the thinking and accumulate facts and data, but 
the interpretation and weighing is left to the decision-makers. Pure deliberation of 
the alternatives in the discussion among decision-makers and experts often lead to 
decisions of low transparency and may lack consistency. Simulating the impact of a 
new policy in a health economic models or trade-off models would limit the factors 
to be considered.
MCDA is an umbrella term for decision support tools which can be used in 
situations like presented here for the Chinese insurance policies, where (1) there 
are one or several clearly stated objectives that stakeholders groups and/or decision-
makers value differently [20], (2) there are several alternative options how to fully 
or partially reach these objectives, and (3) there multiple criteria, which can be 
integrated into a calculable composite measure of the benefit or worth of the vari-
ous alternatives [21]. Among the MCDA methods are the analytic hierarchy process, 
weighed sum and weighed product models, or ranking and simple multiattribute 
rating techniques (SMART) as described below [22, 23].
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A taskforce of the International Society of Pharmacoeconomics and Outcomes 
Research (ISPOR) has described the MCDA process for the use in health-care 
decisions [24, 25]. Generally, the process includes six steps, and is adapted based on 
the specific decision problem, objective, and context. The definition of the decision 
problem is the first step. Subsequently, agreement needs to be reached among the 
stakeholders to determine which criteria are useful to determine the alternative 
option that will best solve the decision problem. If the importance of these defined 
criteria differs, the stakeholders also should agree on the weight (relative impor-
tance) of each criterion in the assessment of the alternative options.
Finally, in the assessment of the alternatives, each criterion is scored separately and 
contributes with the predetermined weight, to the composite score that reflects the 
overall performance of each alternative. As decisions in healthcare often impact a wide 
range of stakeholders, the criteria may also be chosen to accommodate different stake-
holder perspectives [26]. MCDA is being used widely across health-care systems to 
inform decision-making in healthcare, including benefit-risk assessment of medicines, 
formulary listings, purchasing, or reimbursement decisions [25, 27–29]. MCDA has 
specifically been suggested as an evidence-based health technology assessment (HTA) 
tool for evaluating off-patent pharmaceuticals in developing countries [30]. Examples 
for using MCDA in decision-making for off-patent medicines in developing countries 
are emerging in several countries such as China, Thailand, Indonesia, or Egypt [31–34].
A short explanation of MCDA in lay language (English) can be viewed in the 
online material to this book and via the Internet (https://www.youtube.com/
watch?v=7OoKJHvsUbo).
1.4 Policy initiative in China
The objective of this initiative was to collaborate among provincial insurance 
policy leaders in China to create an MCDA tool to evaluate insurance policy options 
across China. This collaborative process was intended to provide a transparent 
prioritization of insurance models to guide provinces in the decision process. A 
secondary objective was to adapt a globally validated MCDA in a local environment 
to address a specific decision problem.
2. Process for adaptation of a global format
MCDA is a method to support decision-making, while allowing for adaptation 
to a specific decision problem. The methodology, framework, and process applied 
in the workshop followed a previously developed and validated model (Figure 1) 
[30, 33] for adaptation to a new decision problem and context. Each of the phases 
will be described in detail below.
2.1 Workshop preparation
To achieve broad buy-in and acceptance for the tool, many of the important 
stakeholders should be included. Through participation in an interactive workshop, 
individual stakeholders will be able to see exactly how the tool was developed and 
can contribute their perspective to shape the new tool. In order to limit the work-
shop to less than 1-day preparation prior to the workshop is important. Ideally, 
the definition of the decision problem should occur prior to the workshop. For the 
initiative described here, decision problem was the assessment of health-care policy 
options across China (see Section 1.4).
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2.1.1 Stakeholder engagement
One of the core principles of designing and implementing change is that the 
key stakeholders are considered throughout the process according to their respec-
tive position in the context of the change. The design and implementation of 
the new insurance policies will be the responsibility of the provincial insurance 
authorities under the conditions outlined by the national policy framework. They 
will not only have to be convinced by the new insurance model and its feasibility, 
but they will also have to defend any new design versus the outside stakeholders 
such as provincial policy-makers, provincial urban employers, and provincial 
urban employees, and toward the inside stakeholders who will be charged with 
the implementation.
In this initiative, the analysis started by listing all impacted stakeholders who 
hold influence over the proposed change in program. Each of the stakeholders was 
rated by their level of interest in the insurance policy and the level of influence 
(power) they have in relation to the new policies.
For the development of the decision tool, these medical insurance representa-
tives were invited to participate in the workshop. In addition, academic policy 
influencers and public health experts participated in the presentations and 
discussions.
In the subsequent steps of piloting, validation, and full implantation (beyond 
the described workshop), a broader range of stakeholders has to be involved or 
managed to ensure that their interests are represented, and the decision principles 
are accepted by expanded stakeholders.
2.1.2 Adaptation of global format to the decision problem
As outlined in the introduction (see Sections 1.1 and 1.2), the national policies 
could benefit by improvements in the insurance coverage scheme for urban employ-
ees. To accommodate the comparison of alternative insurance policies a multicri-
teria decision tool was created to test how well each insurance option addressed 
national and provincial requirements.
For this, a set of requirements was identified through desk research and discus-
sion with policy-makers and academic health policy experts before the workshop by 
the core team, which led to the base set of evaluation criteria.
Figure 1. 
Process applied for adapting a previously developed MCDA tool and framework to the decision problem of 
developing new insurance policies in China.
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2.1.3 Proposed decision criteria
Preliminary criteria were identified in the five domains presented in Figure 2: (1) 
funding and finance, (2) access, (3) policy priority (access), (4) equity, and (5) likeli-
hood of change. Each of the domains contained two or three criteria as defined below 
with a total number of 11 criteria. Of the five domains, two ((2) access and (3) policy 
priority) were related to access. While more criteria had been considered, it was impor-
tant to manage the number of criteria. The relevance and feasibility of the proposed 
criteria was further challenged in the workshop by the participating stakeholders.
Under the domain of “funding and finance,” two criteria were proposed. The 
criterion “financial impact for insurance” should help to roughly estimate the finan-
cial risk of a potential future health policy on health-care expenditure to be covered 
by the insurance scheme in comparison to the current insurance expenditure. To 
estimate the impact of a future insurance model on overall extent of insurance 
expenditure would be available as funding for healthcare, a criterion “mobilization 
of funding for outpatient healthcare (HC)” was proposed.
To assess the impact of a future policy on overall “access” for patients to health-
care, three criteria were predefined. With the criterion “access to pharmaceuticals,” 
the impact of a new insurance model on patient access to ambulatory pharmaceuti-
cal therapies as compared to the current system should be assessed. As most of 
the ambulatory care is made up by pharmaceuticals, which currently are to a large 
extent paid by the patients out-of-pocket, improvement in this area would be a 
major achievement. To compare the expected impact of the new model on overall 
coverage for healthcare in the outpatient setting, the second criterion “outpatient 
coverage” was suggested. The third criterion “economic burden for patients” was 
introduced to assess the impact of the potential future health policy on the patients’ 
finances in comparison to the current system.
A separate domain named “access/policy priority” was put forward for discus-
sion in the workshop to emphasize the need of meeting the policy priorities set by 
the national government policy. The first priority to be addressed is “timely inter-
ventions” (care when it is needed) to assess the impact of the future model on time 
to care (initiated by patient, family member, or insurance model). The intent here 
is to decrease the hurdles or improve the motivation for searching for healthcare 
early in the disease process instead of waiting until reaching more severe disease 
states before seeking care. The second criterion in this domain, “primary care 
utilization” is meant to help determine the impact of the future policy on the use of 
primary care in comparison to the current system. The policy objective emphasized 
Figure 2. 
Five domains for assessing the impact of insurance policy options on the intended outcomes of the policy changes.
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by this criterion is to shift care more toward the primary care level with much lower 
hurdles for patients as opposed to the current practice of accessing care mostly 
through specialized hospital services.
Two criteria were attributed to the domain of “equity.” “Solidarity for outpatient 
HC” appeared an important criterion to compare the impact of the new policy 
system on the solidarity principle. Full solidarity would mean equal health-care cost 
to everybody independent from personal health status. Furthermore, the impact of 
the future insurance model on health-care equity as compared to the current situa-
tion should be captured under the criterion of “equity.” This could potentially also 
imply higher contributions for people with higher income.
An important aspect to look at is the feasibility of introducing a new insurance 
policy model. This was to be addressed by the domain of “likelihood of change.” The 
criterion “ease of transition,” required an estimate of the smoothness of transition-
ing from the current to the future model. A specific criterion “acceptability to 
stakeholders” was proposed to account for the resistance of key stakeholders toward 
changing from the current to the potential future system. The final domains and 
their related criteria are presented in Table 2.
2.1.4 Proposed scoring for the decision criteria
For each of the proposed criteria, a scoring scale was developed. The scoring 
definitions were mostly qualitative assessments and nonlinear. For example, the 
possible outcomes and related scores for “financial risk for insurance” were high 
risk of nonmanageable cost increase (exclusion), increased but manageable cost increase 
(25%), minimal cost increase expected (50%), same cost as current (75%), decreased 
cost to insurance expected (100%). In this example, exclusion means that an insur-
ance option would be immediately excluded which can, with reasonable certainty, 
be expected to lead to massive financial impact to a degree which may bankrupt 
the insurance. Another example of a proposed scoring is the criterion of “equity” 
with the possible outcomes of “high degree of HC differences within population” 
(0%), “limited improvement of HC equity” (25%), “(limited) improvement of HC 
equity” (50%), “HC equity is mostly satisfied” (75%), “HC is the same for every-
body” (100%).
Except for the score “exclusion,” all scores are expressed in percentages. This 
method provides for a normalization within the scoring system even if each score 
does not have the same number of scoring levels. This also allows for differentiation 
between the importance of the possible outcomes. The final score for each criterion 
will be calculated from the score (in percentage) and the maximum score achiev-
able by this criterion (described in Section 2.3).
2.2 Interactive stakeholder workshop
The interactive stakeholder workshop took place in Beijing, China, on 
September 14, 2018 under the leadership of Professor Shanlian Hu (Fudan 
University). The agenda started with introductory presentations on the policy 
changes which triggered the initiative. The view on the initiative from different 
perspectives (e.g., academic, policy, industry) was presented through a moder-
ated discussion of participants’ expectations and viewpoints on upcoming 
changes and the expected improvements in health insurance schemes. This was 
followed by an interactive component to develop a common general decision 
model following a validated MCDA calculation model and process for local adap-
tation [30, 35]. This portion of the workshop was moderated by two international 
health-policy advisors.
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Gaps in current health-care coverage and insurance 
systems
Expected improvements with a future 
insurance policy
Equity
• There is a high difference of levels of care between the 
provinces (cross-provincial inequity)
Funding/finance
• Ineffectiveness of personal savings accounts
• Wasteful spending behaviors for resources in personal 
savings
• Nontargeted and no purposive dissipation of funds due  
to individual administration of personal savings accounts
Access
• Rudimentary organization of outpatient care
• Coverage breadth is very narrow/limited
Policy priorities
• Lack of a coordinated management system for policy 
changes
• Overuse of tertiary hospitals
• Current focus on procuring what is demanded for
Equity
• Improve the use of effective therapies
• Achieve equality in access
Funding/finance
• Better allocate funding to more effec-
tive therapies
Access
• Expanded coverage in more disease 
areas
• Doctors have more choice for 
prescribing the best suited therapies 
for each patient
Policy priorities
• More holistic and integrated view on 
health-care decisions
• Striking the balance between good 
care and financial feasibility
• Supplying effective therapies needed 
by the patients
General
• Allow for more flexibility by having a 
solid decision system and guidance
• Allow for pilot schemes in hospitals 
and pharmacies
Table 1. 
Summary of current insurance system shortcomings and expected improvements for future policies.
Because the workshop facilitators spoke English, the entire workshop was sup-
ported by simultaneous translation to ensure involvement, understanding, and con-
tribution of all participants. All materials were made available in the both languages.
The flow of the interactive part of the workshop is depicted in Figure 3.
2.2.1 Discussion change objectives
Each insurance representative had the opportunity to address shortcomings of 
the current system and their expectations for an improved insurance scheme. The 
key statements resulting from this discussion are summarized in Table 1. These 
shortcomings and expectations were well aligned with those proposed by the core 
team during the workshop preparation. Overall, there was high concordance among 
the participants.
Finally, participants shared a common voice that the workshop would yield a 
tool to choose the most rational insurance system to meet the needs of their provin-
cial environments, while still maintaining national consistency.
Figure 3. 
Six-step process for developing the MCDA tool in a workshop with key decision-makers for prioritizing 
insurance policy options in China.
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2.2.2 Discussion and refinement of criteria
Each domain and their related preliminary criteria were presented and dis-
cussed with workshop participants. The participants confirmed the relevance of all 
proposed domains and criteria except under the domain funding and finance. The 
criterion “mobilization of funding for outpatient HC” was dropped as participants 
stated that concept was covered by the “financial impact for insurance” criterion. 
Thus, these 2 criteria were merged into one and that resulted in 10 criteria across 5 
domains as listed in Table 2.
2.2.3 Discussion and refinement of scoring
The proposed scoring for all criteria was reviewed and general agreement was 
reached that the scoring should systematically apply the same number, levels, and 
results of possible scores. A consistent five-level scoring for each criterion was 
developed, whereby the first criterion would always result in exclusion of that 
insurance option. The scoring is defined in Table 3.
2.3 Model construction
A multicriteria decision analysis was demonstrated in Excel (Microsoft™). 




Financial impact and 
funding for insurance
To estimate the financial impact of a potential future 
health policy on health-care expenditure to be covered 
by the insurance scheme in comparison to the current 
expenditure
Access Access to pharmaceuticals To estimate the impact of a new insurance model on 
patient access to ambulatory pharmaceutical therapies as 
compared to the current system
Coverage for outpatient 
HC
To compare the expected impact of the new model on 
overall coverage for ambulatory care
Affordability: economic 
burden for patients
To assess the financial impact on out-of-pocket cost for 
the patients or family
Policy priority Timely interventions To assess the impact of the future model on time to care 
(initiated by patient, family member, or insurance model)
Primary care utilization To estimate the impact of the future policy on the use of 
primary care in comparison to the current system
Equity Solidarity for outpatient 
HC
To compare the impact of the new policy system on the 
solidarity principle. Full solidarity = equal HC cost to 
everybody independent from personal health status
Equity To estimate the impact of the future insurance model 




Ease of transition To estimate the smoothness of transitioning from the 
current to the future model
Acceptability to 
stakeholders
To estimate the resistance of key stakeholders toward 
changing from the current to the potential future system
Table 2. 
Domains and criteria with definitions as determined in the workshop.
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Table 3. 
Outcomes definitions and scoring for each decision criterion.
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domains, criteria, and scoring, there was continuous adaptation throughout the 
workshop to reflect the input of the participants. The final model integrated all 
results from the workshop.
Once agreement had been reached on the domains, criteria, and scoring func-
tions, the participants were guided through the process of ranking the criteria and 
subsequently weighing them for their relative importance.
This involved an anonymous voting with an audience response system (Ombea® 
with OMBEA ResponsePad™) for defining the decision priorities among the list of 
10 criteria (step 4 in Figure 3) and the relative importance of each of the criteria 
in the overall decision (step 5 in Figure 3) following the modified simple multiat-
tribute rating technique (SMART) method for ranking and swing weighing of the 
criteria [29]. For each vote, the result was computed as a median value. The result-
ing model was tested and reviewed using two test cases (step 6).
3. Testing the model
The first step in validating a decision model is testing the model with either 
known or extreme alternatives. During the workshop, there was limited time 
for testing; therefore, we will present two high-level insurance policy options to 
compare using the resulting model from the workshop.
3.1 Potential insurance scheme options
A concern raised during the introduction was that the insurance funds allocated 
to medical savings accounts (MSAs) are not used efficiently. Therefore, a key com-
ponent of health-care reform should include a more effective use of MSA funding.
The goals of a future reform would be to (1) increase the population solidarity 
and foster a more rational use of medical insurance premiums both from the per-
spective of the employee and the employer and thus (2) increase the efficiency of 
how the funds are utilized. In addition, the new policies should support key govern-
ment (national) health-care policy priorities such as (3) a shift health-care utiliza-
tion from tertiary to primary care services, and thus (4) incentivize earlier use of 
health-care services instead of delaying until more expensive inpatient services are 
required (timely interventions).
3.1.1 Insurance model option 1
The scope of payment for personal MSAs would be expanded to include addi-
tional services such as deductible (user fees) of hospitalization medical expenses, 
or for the medical expenses of other family members, paying the premiums of 
commercial medical insurance participation. Thus, insured employees would have 
more options for MSA spending and would still make individual decisions on when 
and how the money would be spent. This option would not provide an incentive to 
increase the use of outpatient care.
3.1.2 Insurance model option 2
A pooled outpatient funding system for the urban employees’ medical insur-
ance would be established, similar to how current inpatient service is funded. This 
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would create a gradual transition of payments into the coordinated population fund 
instead of the MSA and ultimately absorb the remaining funds in current MSAs. 
In this option, the decision on funding allocation would be made by the insurance 
authority or government across the entire insured population for both outpatient 
and inpatient care. Proactive funding of outpatient care would be intended to 
decrease inpatient care down the road.
3.2 Comparison of options
Four members of the project team and two additional Chinese health-care 
experts used the MCDA model to independently rate the two insurance policy 
options. Their answers were evaluated using the following rules:
a. If three or four of the raters answered identically, this was taken as the result for 
that attribute;
b. If the answers were distributed, the median result was used;
c. If the median was between two scores, the answers from the Chinese respond-
ents were given a higher weight;
d. If the result was between two scores, the more conservative response was chosen.
Following this approach, insurance option 2 was rated with a total of 78.0 points 
as the superior policy as compared to insurance option 1 with a total of 53.95 points. 
The detailed results are shown in Table 4. Insurance option 1 scored better for 
the attributes relating to “financial impact and funding for the insurance,” “access 
to pharmaceuticals,” coverage for outpatient healthcare, “affordability/economic 
burden to patients,” “timely interventions,” “primary care utilization,” “solidarity,” 
and “equity.” In the final two attributes “ease of transition” and “acceptability to 
stakeholders,” insurance option 1 was rated higher.
This example shows that there is a trade-off in any decision-making process—in 
this case between the domain “likelihood of change” where option 1 scored higher 
and for the other four domains, where option 2 scored higher. The model high-
lighted these trade-offs and made them more transparent. Once policy-makers 
agree on their final decisions, they are also more aware of what resistance may be 
expected and therefore may be better prepared to consider preventive measures to 
minimize such resistance.
3.3 Model observations
The intention of model testing was to understand (A) ease of use of the model 
for those using the model and (B) to see how consistent the answers are between 
different users.
To answer the first question, the users were specifically asked about their experi-
ence. The model was rated to be very easy (1) or easy (2) and neutral by two raters.
The interrater consistency varied depending on both the attributes and the 
insurance option. For most questions, there was a clear preference for one score. 
The highest response variability was observed for option 1 in relation to “financial 
impact and funding for insurance,” “primary care utilization,” “ease of transition,” 
and “acceptability to stakeholders.” The responses for option 2 had less variability.
In order to improve the interrater variability, two improvements were sug-
gested: (1) provide the raters with a more detailed description of the meaning of 
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an attribute and a score and (2) provide more a more detailed description of the 
two insurance models. An additional step of deliberation where a discussion could 
be led between the raters could give the rational for their individual ratings and 
consensus could be developed in the process. The latter approach would help to 
Table 4. 
Scoring of option 1 and option 2 in the MCDA model for the comparison of insurance models in China as rated 
by six test persons (four Chinese, two international).
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improve the cross-rater understanding as a part of the implementation and training 
process and enhance the consistent use of the model over time.
Two raters proposed to reduce the numbers of criteria for some of the options, 
because it may be difficult to determine the exact response if the gradual differences 
between the possible answers become too small.
We would propose when applying this model to a decision problem the interra-
ter variability should be monitored throughout the introduction phases. The results 
of these evaluations will help to improve the model over time.
4. Implementation process
Before releasing the model to provincial insurers, further pilot testing would be 
recommended. Ideally, a selected group of insurance experts would be asked to use 
the model in the assessment of their own insurance options and, in parallel, the two 
“standard” options as described above.
After the evaluation, the pilot users should be interviewed for their experience 
in the process and suggestions for improvement. This feedback could be used for 
building a next version tool, which could then be presented to the State Medical 
Insurance Bureau and released to a broader user group. In addition, guidance and 
training material should be developed to support interrater consistency in the 
application of the model. Dissemination could happen via various channels such as 
the State Medical Insurance Bureau or presentations and workshops at provincial or 
national conferences where insurance policy experts come together.
As mentioned above, the use of the model should be accompanied by an ongoing 
collection for user feedback (e.g., in an online survey format) and regular revision 
of the tool for further adaptation to new application requirements.
5. Discussion
5.1 Transferability within China
At the end of the first workshop, participants found high value in the MCDA 
approach toward building a criteria-based decision tool. In particular, they appreci-
ated the experience with the MCDA methodological approach which can be applied 
to decisions in technology assessment based on predefined requirements.
Yu et al. warned in a recent publication that “if supply-induced demand is not 
effectively controlled, a universal and uniform social health insurance may be more 
harmful than beneficial in China” [36]. By substituting the existing fee-for-service 
design with bundled provider payment policies, there can be more integrated 
approaches for smaller population groups that exist in China [37]. However, this is 
only possible, if allocation of funds for outpatient services is made by health-care 
decision-makers, guided by considerations of equity, access, and efficiency in 
public healthcare. Tools such as MCDA will improve transparency and consistency 
in health-care decision-making. Although the decision on the future UEBMI policy 
will be made on a provincial level, the evaluation tool will assist the decision-mak-
ers to go through a set of rational decision considerations (criteria) before selecting 
the most appropriate option. A consensus process, validated through a pilot testing 
phase, will provide a high level of legitimacy to the decision-making process.
UEBMI is the insurance system for urban employees. The other insurance 
options for urban residents (URBMI) or for rural citizens (NRCMS) could use 
similar tools for further developing their insurance options or to design a merged 
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insurance policy [38]. However, it should be noted that the three systems vary in 
terms of financing mechanisms, funding extent, and coverage policies and would 
require a full adaptation of the model. In addition, the stakeholders involved in 
the process might differ. For example, consumers or patients could be included as 
important stakeholders, because URBMI and NRCMS are voluntary systems and 
not mandatory by employment.
The described methodology could also be transferable to other types of decisions 
in China, such as which products should be listed or reimbursed, or which of the 
available alternatives should be purchased [30]. Such an application is presented in 
another chapter of this book at the example of purchasing off-patent pharmaceu-
ticals in hospitals in Thailand [39]. However, successful adaptation of the meth-
odology for each new type of application requires a thorough process described in 
Figure 1 of this report, including preparation, involvement of the decision stake-
holders, and phased implementation [33].
5.2 Country transferability
Many countries moving toward Universal Healthcare Coverage are building up 
their health-care systems and coverage policies. They will face similar decisions 
throughout this process. Although the instrument described here has been devel-
oped for the needs of the Chinese stakeholders in the context of the current insur-
ance policies, the process and the principles can be transferred to other countries. 
This structured and transparent approach for planning and implementation can 
provide learnings for improvement of health-care insurance policies.
5.3 Key learnings, challenges, and limitations
By using a structured and previously validated process for developing a decision 
support tool [33], we were able to work with key stakeholders from several prov-
inces in China during a 1-day workshop to apply the tool to a decision problem. The 
resulting MCDA spreadsheet model can be used by UEBMI insurance policy-makers 
in the provinces of China to compare new options of insurance policies.
A few key components in the process are essential for successful implementation. 
The most important is the engagement of the stakeholders impacted by the decision. 
Through the engagement of all stakeholders, a variety of factors can be considered 
and an open exchange is possible through a workshop format to incorporate all 
perspectives [40]. In addition, stakeholders, who are part of the “inner circle,” or the 
guiding coalition, can further to convey the momentum for change. This becomes of 
utmost importance once full implementation is realized [37, 40, 41]. In our example, 
the decision to limit the stakeholders to insurance experts and academic health 
policy leaders was purposeful to reflect the current decision-makers. However, a 
broader range of stakeholders may be involved in the testing phase of individuals’ 
provinces or countries.
Another key success factor is to clearly define the decision problem at the outset 
of the stakeholder collaboration. If there is a general agreement on the objective of 
the new policy, and on the criteria, which help to measure whether the objectives 
can be achieved, the MCDA tool offers an opportunity for increasing transparency 
of the decision process. Increased transparency may also contribute to a higher trust 
in the policies by the public in China [42].
The participants in the workshop cautioned that it may be necessary to adapt such 
a model in their respective provinces to address provincial health-care priorities, 
which may differ from province to province. A practical implication was use of the 
domains and criteria as a checklist for the design of new insurance policy options.
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Finally, for the long-term success of any future policy change, measurement of 
outcomes is important. The criteria used in the selection process could become key 
performance indicators around population health and economics as used in other 
evaluations [2, 5, 43].
Some limitations or pitfalls of using MCDA as a decision support tool need to 
be considered. First, there is a risk of bias in the MCDA when the criteria overlap 
and therefore overemphasize certain aspects of the evaluation. In our example, 
the participants felt this to be the case with the two finance-related criteria which 
were originally proposed. They, therefore, decided to merge the two criteria into 
one. Second, the ranking and weighing methodologies can have a high impact on 
the “resolution” capability of the decision support tool. In this chapter, we have 
used a modified SMART approach to MCDA which has been recognized broadly 
as practicable [23, 39]. It should also be emphasized that decision-makers may be 
tempted to use the summary score as “the decision argument.” Instead, decision-
makers should deliberate and compare the entire rating profile to confirm, that 
the instrument and the summary score have validity in the specific comparison. 
This will allow a more differentiated argumentation and documentation why 
a specific decision has been taken and which preventive measures should be 
taken to overcome the areas of weaknesses of the chosen option, which are those 
criteria, where it scored low.
There are also a few limitations to our proposed process. In our workshop, 
only a limited number of stakeholders were represented. Future programs 
should aim to achieve a good balance between all relevant stakeholders to 
maintain an active dialog during the workshop and manage the number of 
participants to avoid limitation of discussion. Preparation through stakeholder 
research, including mapping and assessment of appointments, is important to 
strike this balance.
Another limitation was the need to work with translators during the entire 
process, which was due to the international composition of the project management 
and moderating team. To minimize the risk for misunderstanding, the workshop 
was simultaneously translated and all materials, including the model, were available 
in both English and Chinese language.
6. Conclusions
In this report, we have demonstrated how an internationally developed and 
validated process based on MCDA methods was adapted to decide which funding 
model should be selected for the future UEBMI insurance policy in the provinces 
of China. The processes included extensive stakeholder analysis and engagement as 
well as an interactive workshop for building consensus on objectives of the reforms, 
the criteria for success, and the measures for scoring such criteria.
The advantage of combining stakeholder driven cocreation with the principles 
of multicriteria decision analysis was to build a model with the input and final 
consensus of key stakeholders that still allows for local adaptation of criteria, 
weighing, and scoring. Using such a structured decision model fosters consistency 
and transparency across all decisions and allows for documentation of the decision 
process and evaluation of the impact.
We would like to end this report with a specific concluding comment of one 
of the workshop participants: “It is hard to predict the future; but using a rational 
method to approximate the future needs for insurance models will help me to 
convince my constituents.”
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Abstract
India is the second most populous country in the world with a population of 
1.3 billion; any change in its morbidity and disability pattern is bound to bring 
change at the Asia level, which is a matter of concern for the developing countries. 
Disability-free life expectancy (DFLE) and disability-adjusted life years (DALYs) 
provide summary measures of health across characteristics. The assessments of epi-
demiological patterns and health system performance of any place and time period 
display its progress towards the goal of sustainable development goals (SDGs). The 
main aim of this study is to assess the age and sex pattern of the burden of diseases 
(mortality and morbidity) and disability in India. The information on disease and 
deaths was extracted from the 71st round of the National Sample Surveys (NSS) 
conducted in 2014 (NSS 2014) and the Causes of Deaths Study conducted in the 
2010–2013 (RGI 2010–2013) and disability from Census of India 2011 (ORG 2011). 
Keywords: morbidity, disability, age, sex and India
1. Introduction
The main aim of the Millennium Development Goal was to remove poverty and 
improve health. With the end of MDG goals in 2015, a new set of sustainable devel-
opment goals (SDGs) were proposed to be achieved by the year 2030. The third goal 
of SDG is to ensure healthy lives and promote well-being at all ages. Reducing the 
prevalence of non-communicable disease (NCD) is one of the targets of SDG Goal 
3. According to Global Burden of Disease Study 2015, DALYs due to communicable 
disease fell from 1200 million in 1990 to 7416 million in 2015, whereas total DALYs 
due to non-communicable diseases increased from 1.1 billion to 1.5 billion in 2015. In 
2015, communicable accounted for 30.1% of the global DALYs; non-communicable 
disease accounts for 59.7% and injuries 10.1%. Since 2005, DALYs for the major com-
municable causes have declined substantially except for a few subsets of infectious 
diseases [1]. The life expectancy at birth in India has increased from 49.7 years in 
1970–1975 to 68.3 years in 2011–2015 [2]. The life expectancy has increased from 
23.7 years in 1881 to 66.9 years in 2011–2015 for males and from 25.6 to 70.0 years for 
females during this period [2, 3]. Further, infant mortality rates reduced from 130 
to 37 deaths per 1000 live births from 1970 to 2015 [4, 5]. Child and adult mortality 
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rates have also declined significantly [6, 7], and there has been a significant increase 
in the probabilities of surviving to age 60 and 70 [8, 9].
With the significant improvement in life expectancy [10], there has been a 
gradual shift in the age distribution of deaths and disease pattern [11]. The numbers 
of DALY and DALY rates dropped substantially for communicable disease group 
between 1990 and 2016. By contrast, numbers of DALYs increased substantially for 
NCDs. The all-age prevalence of the most leading NCDs increased substantially in 
India from 1990 to 2016 [12]. Communicable diseases were the major causal agent 
of mortality in the early 1970s. However, mortality and disease burden are gradually 
moving towards non-communicable diseases. The premature deaths are shifted to 
the years lived with disability [13]. The communicable diseases are more concen-
trated in the people of the lower socio-economic group, and non-communicable 
diseases are on the rise due to current changes in India’s population age structure 
and improved economic status and lifestyles [13, 14]. In this transition period, 
studies to understand the relationship between mortality and morbidity has become 
imperative for giving useful feedback to programme and policy planners who are 
involved in the public health management.
Studies on mortality and morbidity at the country level have taken central place 
in the social research domain from several decades (Figure 1). Studies addressing 
the pattern and cause of mortality and morbidity are scarce in India due to paucity 
of data. This issue has already been studied in the developed countries exhaustively. 
India is recently going through a phase of both demographic and epidemiological 
transitions. Health condition has improved along with increasing life expectancy. 
However, increase in life expectancy is accompanied with the loss of healthy life 
years. There is a need to examine the recent levels and age pattern of morbidity and 
its relation to the mortality in the context of India. The main aim of the paper is to 
see the age pattern of self-reported morbidity by sex in India and to estimate the 
burden of reported morbidities with a special focus on communicable and non-
communicable diseases and disability by age and sex. This paper aims to provide an 
overall picture of the disease burden on the context of health and social develop-
ment and throws light for policy investment and future research.
2. Data and methods
We have used 71st round of the National Sample Survey (NSS) data conducted 
in the year 2014. The 71st round was conducted in two subrounds of 6 months each. 
Figure 1. 
Change in morbidity prevalence in India from 2004 to 2014.
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The NSS provides information about the different communicable and non-com-
municable diseases on any person in surveyed household who were found ill during 
the last 15 days from the date of survey. Causes of Death data were extracted from 
the Causes of Death report published by the Registrar General of India (RGI), New 
Delhi, during 2010–2013. We used cause-specific proportion of deaths for com-
municable and non-communicable diseases by age and sex. The 2011 census, which 
covers the entire population of India, provides reported information on seven types 
of disability and one category for multiple disabilities. The prevalence of disability 
by age and sex is taken from the 2011 census. The proportion of total deaths by age 
was extracted from the report of Sample Registration System 2006 [15].
Self-reported ailments were classified into three categories: communicable 
disease, non-communicable disease, disability and ‘other’. The main independent 
variables considered in this study are age and sex. The other individual socio-demo-
graphic factors considered in the analysis are residence, educational attainment 
and monthly per capita expenditure quintiles. Descriptive statistics and bivariate 
analysis are used for description of prevalence of diseases and disability and its 
association with age group. Logistic regression analysis is used for multivariate 
analysis.
The prevalence of disease was calculated with information from the survey on 
any person who had fallen ill during the last 15 days from the date of survey:
  Prevalence =  Number of diseased persons during the reference period    _______________________________________   Total population during the same time period × 1000 (1)
Summary measures of the health of a population are calculated by combining 
data on mortality and non-fatal health outcomes into a single number – disability-
adjusted life years (DALYs) and disability-free life expectancy (DFLE) are calcu-
lated by age for male and female population in India.
Disability-adjusted life year measures health gaps as opposed to health expectan-
cies. It measures the difference between a current situation and an ideal situation 
where everyone lives up to the age of the standard life expectancy in perfect health. 
The DALY combines in one measure the time lived with disability and the time lost 
due to premature mortality:
  DALY = YLL + YLD (2)
where YLL is the years of life lost due to premature mortality and YLD is the 
years lived with disability.
The computation formula for YLL is given by:
  YLL =  (N / r) ×  (1 −  e −rL ) (3)
where N is the number of deaths, L is the standard life expectancy at age of death 
(years) and r is the discount rate (e.g. 3% corresponds to a discount rate of 0.03).
Similarly, the formula for YLD is  YLD =  (I × DW × L ×  (1 −  e −rL ) ) / r .
where I is the number of incident/prevalence cases, DW is the disability weight, 
L is the duration of disability (years) and r is the discount rate.
Disability weight was borrowed from the Global Burden of Disease Study 2000.
Sullivan’s health expectancy method reflects the current health of a real popula-
tion adjusted for mortality and disability level and is independent of age structure. 
Health expectancy calculated by Sullivan’s method is the number of remaining years 
at a particular age that an individual can expect to live in a healthy state.
Disability-free life expectancy is one of the prime Sullivan’s health expectancies. 
DFLE is found by partitioning the person year lived in the interval into those who 
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Figure 2. 
Prevalence of different self-reported morbidities in India by Gender (2014).
have lived with and without disability. If we assume two states called disability-free 
and with disability, then the disability-free life expectancy at age x (DFLEx) and the 
life expectancy with disability (DLEx) at age x are defined by:
Years lived with disability between ages x and x + 5 = 5YDx = 5Lx × 5Prevx;
Years lived without disability between ages x and x + 5 = 5YWDx = 5Lx × (1 − 5Prevx).
DLEx = sum of years lived with disability for ages x and above, divided by lx.
DFLEx = sum of years lived without disability for ages x and above, divided by lx.
where lx is the number of survivors at exact age x, 5Lx is the number of years of 
life lived by the life table cohort between ages x and x + 5 and 5Prevx is the preva-
lence of disability between ages x and x + 5 in the population.
3. Results
The prevalence of all self-reported communicable and non-communicable 
morbidities has increased from 2004 to 2014 in India. The prevalence of commu-
nicable diseases increased by 10 points and non-communicable diseases by more 
than 20 points. The prevalence of all diseases was higher for females than males 
(Figure 2). The prevalence of disability was the same for males and females (4%). 
The maximum difference in the prevalence rate was observed for the category of 
non-communicable disease (33% in males and 51% in females) (Figure 2).
The study examines the prevalence rate of self-reported morbidities by age 
and sex in India for the year 2014. Females are at higher risk of suffering from 
disease. Risk of suffering from non-communicable diseases and other diseases 
increased with increasing age and reduced steadily for the communicable disease. 
The infant in the age group of 0–1 year suffered the largest burden of communi-
cable diseases (overall 108 per 1000; male, 121 per 1000; female, 93 per 1000). 
Non-communicable disease prevalence was highest in the age group 70 and above 
(overall 274 per 1000 population; male 281 and female 267). Similarly, other disease 
prevalence remains higher for elderly age 70 years old and above. Male–female gap 
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in the communicable disease prevalence was the highest for the infant age group. 
Females overpass the male prevalence of communicable disease from the age 
group 15–19 years and remain on the higher side except the oldest age group (65 and 
above). The prevalence of non-communicable diseases was higher for females than 
males in all the age group except the 70+ and less than 10 years. Similar pattern by 
sex was observed for the other diseases and disability status (Figure 3).
Table 1 shows the results of logistic regression analysis by age after controlling 
the effect of other socio-economic factors. It is evident from the results that the odds 
of suffering from communicable diseases were maximum in the reference age group. 
The odds reduced significantly in the adult ages and increased steadily afterwards 
in the elderly age groups. This age pattern does not change significantly by sex. The 
lowest odds were observed in the age group of 25–30 (OR, 0.19) and 30–35 years 
old (OR, 0.20). A significant positive association can be seen between risk of suf-
fering from non-communicable disease and age. The risk of suffering from non-
communicable diseases is more than 10 times higher in the age group 40 and above 
with the highest risk in the age group 70+. The risk of suffering from NCD was 52 
times higher for the elderly age 70 and above. Elderly males (70+) have 48 times and 
Figure 3. 
Prevalence of self-reported morbidities by age and sex in India (2014).
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females (70+) 58 times higher odds of suffering from non-communicable diseases. 
With the increase of age, the likelihood of other diseases also increased significantly. 
For other diseases, the impact was greatest for the elderly population in the 70-year 
age group who have three times higher risk than the reference age group. In each age 
group, the odds of suffering from each type of disease were higher among females 
than males except a few age groups in the other disease category (Table 1).
The result for DALYs from Table 2 shows that the burden of communicable 
diseases was highest in the infancy (0–1 years), followed by 1–5 years. The two age 
groups contribute to 60% of the total DALYs in male children and 56% in females. 
The result clearly indicates that the burden of infectious diseases was higher 
during infancy and noticeably greater among males than females. The women in 
the age group 15–49 contribute to 21% of the total DALYs. The age distributions 
of the DALY indicated that individuals aged below 5 and above 60 years were 
more susceptible to infections. The DALYs in each age group are higher for females 
than males except children aged below 5 years and the elderly aged 70+. Females 
in the adult age group were more at risk of having infectious diseases than their 
male counterparts. The age distributions of the non-communicable disease DALYs 
Age group Communicable 
disease
Non-communicable disease Disability and others
Odds 
ratio
95% CI Odds 
ratio





1–4 0.77 0.72 0.82 1.17 0.95 1.43 0.30 0.20 0.44
5–9 0.43 0.40 0.46 1.28 1.05 1.55 0.29 0.20 0.43
10–14 0.28 0.25 0.30 1.39 1.15 1.69 0.29 0.20 0.43
15–20 0.24 0.22 0.26 2.09 1.74 2.51 0.52 0.37 0.71
20–25 0.22 0.20 0.24 2.27 1.90 2.72 1.09 0.84 1.43
25–30 0.19 0.18 0.21 2.74 2.30 3.26 0.96 0.73 1.26
30–35 0.20 0.19 0.22 4.00 3.37 4.76 0.86 0.64 1.14
35–40 0.25 0.23 0.27 6.69 5.64 7.93 0.93 0.69 1.25
40–45 0.31 0.28 0.34 10.66 9.01 12.62 1.24 0.93 1.66
45–50 0.29 0.26 0.32 15.03 12.72 17.76 1.36 1.02 1.82
50–55 0.29 0.26 0.33 18.79 15.91 22.20 1.84 1.39 2.43
55–60 0.30 0.27 0.33 22.16 18.77 26.16 1.45 1.08 1.95
60–65 0.35 0.32 0.40 39.53 33.46 46.69 2.53 1.90 3.37
65–70 0.39 0.35 0.44 39.52 33.40 46.77 2.01 1.46 2.78
70 + 0.38 0.34 0.43 52.09 44.14 61.47 3.15 2.40 4.14
Male
0–1 Reference category
1–4 0.75 0.69 0.82 1.19 0.91 1.56 0.35 0.21 0.60
5–9 0.42 0.38 0.46 1.21 0.94 1.57 0.31 0.18 0.52
10–14 0.25 0.22 0.28 1.27 0.98 1.64 0.22 0.12 0.40
15–20 0.19 0.17 0.22 1.72 1.35 2.20 0.36 0.22 0.59
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(Table 2) indicated that individuals aged above 45 years are more susceptible to 
non-communicable diseases. The largest contribution of the total DALYs in non-
communicable diseases is from the age group 65–70 (males, 14%, and females, 
13%). The result also shows that the adult working age male and female population 
contributes more than half of the total DALYs in non-communicable diseases. 
The DALYs for non-communicable disease are higher in the male population than 
females in most of the age groups contrary to the fact that the prevalence of non-
communicable disease has been higher among females.
Age group Communicable 
disease
Non-communicable disease Disability and others
Odds 
ratio
95% CI Odds 
ratio
95% CI Odds 
ratio
95% CI
20–25 0.18 0.16 0.21 1.85 1.45 2.36 0.38 0.24 0.63
25–30 0.15 0.14 0.18 2.00 1.57 2.53 0.37 0.23 0.60
30–35 0.15 0.13 0.18 2.82 2.23 3.56 0.41 0.25 0.67
35–40 0.18 0.16 0.21 4.51 3.59 5.67 0.61 0.38 0.96
40–45 0.21 0.18 0.24 7.47 5.96 9.36 1.00 0.65 1.54
45–50 0.21 0.18 0.25 10.85 8.69 13.55 1.05 0.68 1.62
50–55 0.26 0.23 0.31 14.11 11.30 17.61 1.57 1.04 2.37
55–60 0.26 0.23 0.30 17.37 13.95 21.63 1.51 1.01 2.27
60–65 0.31 0.27 0.37 33.57 26.93 41.84 2.53 1.69 3.80
65–70 0.38 0.32 0.45 31.30 25.05 39.11 1.87 1.18 2.96
70 + 0.35 0.31 0.41 48.27 38.81 60.02 3.05 2.08 4.48
Female
0–1 Reference category
1–4 0.79 0.71 0.87 1.14 0.83 1.57 0.24 0.13 0.44
5–9 0.44 0.39 0.49 1.37 1.02 1.85 0.28 0.16 0.49
10–14 0.31 0.27 0.35 1.57 1.17 2.10 0.37 0.22 0.62
15–20 0.30 0.27 0.34 2.61 1.98 3.45 0.69 0.44 1.06
20–25 0.26 0.23 0.29 2.79 2.13 3.65 1.66 1.16 2.37
25–30 0.24 0.22 0.27 3.69 2.83 4.80 1.51 1.05 2.18
30–35 0.27 0.24 0.31 5.71 4.39 7.43 1.35 0.92 1.98
35–40 0.34 0.30 0.39 9.79 7.56 12.69 1.27 0.85 1.90
40–45 0.44 0.39 0.50 15.05 11.63 19.47 1.48 0.99 2.22
45–50 0.39 0.34 0.45 20.63 15.98 26.63 1.66 1.12 2.48
50–55 0.33 0.29 0.38 24.70 19.14 31.88 2.06 1.40 3.04
55–60 0.36 0.31 0.41 28.81 22.33 37.18 1.39 0.91 2.12
60–65 0.41 0.35 0.48 47.49 36.77 61.33 2.52 1.68 3.79
65–70 0.41 0.34 0.49 51.15 39.51 66.21 2.16 1.38 3.39
70 + 0.42 0.36 0.49 57.55 44.59 74.28 3.25 2.20 4.79
Table 1. 
Logistic regression analysis with the disease status as a dependent variable.
Evaluation of Health Services
38
Communicable Non-communicable
Age group DALY per 100,000 DALY per 100,000
Male Female Male Female
0–1 2896 2489 470 320
1–4 641 541 104 70
5–9 233 236 154 130
10–14 217 221 143 122
15–19 102 163 204 173
20–24 109 167 219 176
25–29 118 174 236 184
30–34 128 156 493 374
35–39 126 154 484 372
40–44 135 177 517 425
45–49 128 125 748 634
50–54 145 149 845 759
55–59 166 172 1073 767
60–64 151 157 971 702
65–69 185 188 1191 841
70+ 102 96 472 307
Table 2. 
Burden of communicable and non-communicable disease by age and sex for total population in India, 2011.
Total life Proportion with disability (πx) Disability-free Suffering
Expectancy (ex) Life expectancy Disability life years
Age 
group
Male Female Male Female Male Female Male Female
0–1 65.8 69.3 0.046066 0.050826 58.1 61.5 7.7 7.8
1–4 67.9 71.7 0.046066 0.050826 59.9 63.6 8.0 8.1
5–9 64.6 68.7 0.072173 0.07391 56.7 60.7 7.9 8.0
10–14 59.9 64.0 0.174172 0.169639 52.3 56.4 7.6 7.7
15–19 55.1 59.3 0.174172 0.169639 48.3 52.4 6.8 6.9
20–24 50.4 54.6 0.161413 0.149764 44.5 48.6 5.9 6.0
25–29 45.8 50.0 0.161413 0.149764 40.7 44.7 5.2 5.3
30–34 41.3 45.4 0.140982 0.128796 36.9 40.8 4.4 4.6
35–39 36.8 40.8 0.140982 0.128796 33.1 36.8 3.8 4.0
40–44 32.5 36.2 0.123556 0.106899 29.4 32.8 3.1 3.4
45–49 28.3 31.7 0.123556 0.106899 25.7 28.7 2.6 2.9
50–54 24.2 27.2 0.095472 0.089786 22.2 24.8 2.0 2.5
55–59 20.4 23.0 0.095472 0.089786 18.7 20.9 1.7 2.1
60–64 16.9 19.0 0.093039 0.106845 15.6 17.2 1.3 1.7
65–69 13.6 15.4 0.093039 0.106845 12.7 14.1 1.0 1.3
70+ 10.9 12.3 0.059046 0.074803 4.1 4.2 6.9 8.1
Table 3. 
Burden of disability by age and gender in India, 2011.
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The DFLE result (Table 3) shows that at birth, males in India are expected to 
live 58 years of life without disability out of the 66 years of the total life expectancy 
at birth. Similarly, females are expected to live 62 years of life without disability out 
of the total 69 years of life expectancy at birth. The age pattern of disability-free 
life expectancy does not change considerably till the age 70 in India. The elderly 
population aged 70 years and above are expected to live around two-thirds of their 
life in disability. Elderly males aged 70 years and above are expected to live 63% and 
females 66% of their total life with disability.
4. Discussion
The paper aims to examine the age and sex pattern of morbidity and its linkage 
with summary measures of health such as DALY and DFLE. India is also experienc-
ing a similar epidemiological transition along with demographic transition. It is 
observed that during transition period, the age pattern of mortality and morbidity 
will be altered [16]. There has been a significant transition in age pattern of mor-
bidity in India. A comparison of this study with other previous studies’ findings 
suggests that the age-specific communicable and non-communicable diseases have 
increased over the last 20 years’ time. The increase in the rate of non-communicable 
disease was much higher. With the increase in age, prevalence and odds of suf-
fering from non-communicable diseases increase significantly. The risk of non-
communicable diseases increases from middle-aged adults to elderly population 
among males, and for females, the risk of having non-communicable diseases was 
significantly higher among the elderly age group. This finding supports the previous 
studies’ findings that communicable diseases are more likely to occur in the younger 
ages while non-communicable diseases occur in the elderly population [17, 18].
The study further shows that the prevalence of self-reported non-communicable 
morbidities and disabilities was higher among females than their male counterparts 
in each age group and communicable. Gender gap in health and mortality exists all 
over the world. The unequal utilization of health care is the major factor that leads 
to uneven health disparity. Various reasons for differential morbidity are kinship 
system, gender ideologies, poverty, nutritional status, socio-economic condition, 
level of education and violence [19, 20]. The age pattern of the disease also suggests 
that the prevalence of communicable and non-communicable diseases was higher 
among the females, but the gender gap was not apparent in disability.
In order to understand the burden of communicable and non-communicable 
disease for male and female population in India, we calculated the disability-
adjusted life year. The result shows that the burden of communicable disease was 
higher in infant males compared to infant females in India during 2014. In medi-
cal terms, it is seen that male children are more biologically weaker than female 
children and thus are more prone to various diseases and spend a larger amount of 
time fighting for the disease [21]. Contrary to the prevalence sex pattern, DALYs for 
non-communicable diseases in each age group were higher for males as compared 
to the females. The burden of non-communicable disease was more prominent in 
higher age group (60 years and above) of population across both sexes. The result 
also shows that the adult working age male and female population (15–59 years) 
contributes half of the total DALYs in non-communicable diseases, which is a seri-
ous cause of concern. The socio-economic impact of this morbidity and disability 
due to non-communicable diseases is enormous since these deaths often affect the 
main income earner in the household and those who rear those children [22].
The DFLE result shows that elderly 70 years and above are spending more than 
one-third of their life in disability. Further, females spend more life suffering from 
Evaluation of Health Services
40
disability as compared to males. Due to higher life expectancy among females in the 
later ages, females spend more suffering years. The previous study for the earlier 
decade also suggests that the gender inequalities in DFLE are more evident in India 
and other low- and middle-income countries [23].
5. Conclusions and limitations
India’s population is increasing at a tremendous rate. With increase in popula-
tion, the prevalence of morbidity is also increasing. In spite of the vigorous efforts 
to reduce mortality and morbidity in India, India is still struggling with its unfin-
ished agenda of restricting communicable disease. On the other side, the prevalence 
of non-communicable is rising rapidly. This leads to heavy double burden of disease 
in India. The prevalence of communicable diseases in the younger ages has become 
a threat for the newly born child, whereas the prevalence of non-communicable 
diseases in middle-aged adult and the older ages is concerning the adults and elderly 
population. Thus, both the working and dependent populations are in the clutch of 
morbidity and putting a question on the health system. Females are the real victims 
of disease sufferers and disability. The increasing significance of non-communi-
cable disease burden also suggests the need for serious intervention strategies to 
prevent non-communicable disease burden not only for the elderly but also for the 
adult age group. The basic challenge would be to implement appropriate preven-
tion strategies to halt the growing trend in non-communicable diseases against a 
background of infectious diseases, which remain out of control. The increasing 
burden of diseases among working adults and elderly in a country will impose high 
financial hardship on its government and households.
Though this study examines the burden of communicable and non-communica-
ble disease in India, the result presented in the paper should be interpreted keeping 
the following limitation in mind: First, all the diseases estimated in this research 
paper are based on self-reporting rather than medical investigation. Self-reported 
morbidity is the only variable that gives us information about morbidity in the 
absence of information from medical fields. One of the major doubts that arise is 
about the validity of self-morbidity. In the absence of proper knowledge about the 
ailment, cultural and societal factors, lack of media exposure and socio-economic 
condition may lead to under- or overreporting and biasness towards self-reported 
morbidity. The states which are socio-economically well-off report higher morbid-
ity in comparison to the other underprivileged states. A study states that Kerala 
which is the most developed state in country reports higher morbidity than Bihar 
which has lower life expectancy and lower educational level. The adequate measure-
ment of morbidity is one of the important factors that do could give us a precise 
depiction of the prevalence of morbidity [24]. Second, information used (cause 
of death) in calculation of DALY is based on sample survey rather than complete 
enumeration. Third, age- and cause-specific proportion of death was not available 
at state level; therefore, we used the national-level estimate. Fourth, information 
on proportion of disability was given at 10 years of interval, which is bifurcated in 
5 years of interval.
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Evaluating the Efficiency of a 
Collaborative Learning Network 
in Supporting Third Sector 
Organisations in the UK
Scott Steen and John Mellor-Clark
Abstract
Third-sector organisations are a collective term for voluntary and community 
services, charities, and social enterprises. Within the UK and internationally, a subset 
provides a crucial and ever-expanding role in mental health care provision, delivering 
valuable client and community-led services. However, in the UK these organisations 
are under increased pressure to demonstrate their value, and many are constrained 
by scarce resources and lack of expertise. The Service Improvement Learning 
Collaborative was conceived as an innovative model for shared learning to enhance 
the value of this sector in mental health care support, generating a valuable resource 
of practice-based learning and promoting the implementation of effective practices. 
The initiative combines a collaborative learning model with mentorship support 
and in-depth, data analytical profiling. This collaborative involved a network of six 
organisations focused on exploring the maximisation of data quality, the minimisation 
of client attrition, and the optimisation of clinical outcomes. Evaluating the collated 
data helped identify the many unique challenges facing the sector and evidenced the 
model as a pragmatic solution for service quality improvement. This chapter provides 
an overview of the project’s methodology, including its underlying rationale, first year 
of operation, and value of experiential learning for the field.
Keywords: service quality development, collaborative learning networks,  
practice-based evidence, experiential learning, third-sector organisations, mental 
health
1. Introduction
In the UK, Third-Sector Organisations (TSOs) are a collective term for 
voluntary and community agencies, charities, and social enterprises, of which 
a sub-section provides health and social care via independent and value-driven 
services [1]. Recent audits of the whole sector reveal a notable presence, with 
over 160,000 organisations and nearly 1-million employees and volunteers 
operating in the UK [1]. Across many high-income countries, it is an area which 
is growing rapidly as governments seek to harness their innovation and local 
capabilities [1, 2]. Given their nature, TSOs tend to be highly regarded for their 
proximity to the community, welcoming facilities, and the ability to engage 
those with complex and chronic needs [1–4].
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Despite the potential benefits of TSOs, little research has been undertaken to 
evidence their impact and effectiveness [2, 3]. Research applicable to many mental 
health care TSOs in the UK, including systematic reviews [2], national audits [1] 
and interviews with mental health charities [3], highlight the clinical and economic 
barriers affecting the production and utilisation of practice-based evidence (PBE). 
Many are constrained by tight budgets and scarce resources and often exist as ‘micro-
entities’ making bidding processes and research prohibitively expensive [1, 4]. The 
evidence that has been produced has been characterised as low in quality, lacking 
methodological rigour, theoretical modelling, and reliance on non-representative 
stakeholder feedback [2, 3]. Access to learning is equally challenging with constraints 
on resources to review the latest research literature [3, 4].
For TSOs to overcome these challenges, there must be greater alignment of needs 
and priorities between providers, commissioners, policymakers and academic 
institutions. One approach to optimising the production and sharing of knowl-
edge has been to form collaborative learning networks (CLNs) of services using a 
similar treatment model or methodology for generating evidence [5]. By partnering 
with similar providers, these networks enable organisations to explore, share and 
integrate learning across a network, maximising the potential for practice-based 
learning. CLNs have demonstrable potential within the UK mental health care 
sector, having reported success in the Improving Access to Psychological Therapy 
(IAPT) programme [6] and Children and Young People’s [5] services. The IAPT 
programme, which is a national government-funded initiative for English primary 
mental health services, has been an influential driver in generating public domain 
service performance data. Having mandated sessional measurement across all ser-
vices over a decade ago, it has recently achieved pre-and-post outcomes completion 
rates of 98% for clients completing therapy [7]. These high levels of data complete-
ness are essential for supporting CLNs [6].
The quality implementation framework (QIF) [8] has been previously used as 
a schematic structure to introduce practice changes, including routine outcome 
monitoring (ROM), within mental health care services [9]. This model synthesises 
25 implementation methods from almost 2000 evaluation reports, comprising 4 
action phases and 14 critical steps [8]. Combined with research on the value of 
CLNs, an initiative was undertaken to bring together multiple TSOs delivering 
mental health care to enhance service quality. This chapter describes the rationale, 
process, and outcome of this initiative across its initial start-up and first year of 
operation using a traditional storytelling structure, with reference to the QIF [8] 
and other implementation frameworks [10–13].
1.1 Telling stories
Implementation science is the scientific study of techniques to enhance the 
quality and effectiveness of health services by advancing the systematic uptake of 
evidence-based practice (EBP) in routine clinical settings [14]. The learning from 
the field demonstrates the gap between what is shown to be effective to what is 
implemented in practice [14]. According to the QIF, in preparation for implement-
ing practice change, agents must assess the host setting and build capacity, meeting 
with the service, analysing its infrastructure, surveying and training practitioners, 
and securing buy-in [8, 9]. Regardless of how well-founded and robust the evidence 
may be, it is no guarantee it will be accepted and readily adopted by stakeholders 
[9, 15]. Persuasive communication is therefore critical for framing research find-
ings for specific contexts to enhance their uptake and impact [16]. The power of 
storytelling is increasingly recognised as an effective technique for transforming 
attitudes, perceptions and behaviours as they summarise concepts simply, quickly 
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and effectively, appealing directly to a stakeholder’s values and interest [16]. For 
instance, within UK mental health care services, storytelling as a technique has 
been associated with rapid improvements in data quality [9]. It is for this reason, 
our chapter aims to share the experiential learning and evaluation of this CLN for 
mental health care TSOs using a traditional storytelling outline, describing its set-
ting, characters, plot, and themes.
2. The SILC story
2.1 Setting
To overcome the challenges of effective service development, a CLN was devised 
to support TSOs in the collection and use of data to inform the future development 
of operational practice. Inspired by the Institute for Healthcare Improvement’s 
(IHI) [12] ‘Breakthrough Series’ Collaborative Model and implementation science 
research [11–14], this initiative intended to break new ground by working in close 
partnership with TSOs to generate evidence and inform quality improvement. The 
framework integrated implementation techniques using plan, do, study, act (PDSA) 
cycles [10] focusing on specific areas of service delivery and, as modelled by the 
QIF, create a structure for implementation [8, 9]. This would become known as the 
service improvement learning collaborative (SILC).
Working in partnership, TSOs were invited to upgrade their measurement sys-
tem to a more sophisticated software platform providing additional reporting fea-
tures relevant for service operation and development [17]. Services were required 
to verify their commitment and autonomy at a managerial, board and trustee level 
to commence on a year-long journey to profile and engage with subject-relevant 
resources and attend monthly mentorship sessions and quarterly overnight residen-
tials. A memorandum of understanding was devised to emphasise that membership 
was contingent on full-service participation and this was incorporated into the 
development of an implementation plan [8, 9].
This project took place over the course of a year, focusing on a different chal-
lenge each quarter, including a focus on data collection, session attendance, 
endings, and clinical outcomes. The project commenced with a planning meeting 
involving introductions, training and attitudinal surveys. With reference to the QIF, 
these steps were undertaken to assess the fit between the organisation’s aspirations 
and readiness for change, allowing for open discussion and early feedback [8, 9]. 
Across the project, there were monthly supportive calls with an assigned mentor 
from the research team, and quarterly in-person residential meetings with fellow 
TSOs, each supported by in-depth data profiling throughout. The purpose of the 
mentorship and residential sessions were to support participants in monitoring 
aspects of service quality and provide supportive feedback mechanisms which, 
according to the QIF, are critical post-implementation support strategies [8]. To 
improve future applications, the end of the year culminated in a summative confer-
ence with fellow mental health services to share the findings from the project’s first 
year in operation [8–10]. A diagram of the SILC CLN model, including the induc-
tion, mentorship, residentials and summative conference, is outlined in Figure 1.
2.2 Characters
The QIF emphasises the criticality in creating an implementation team to 
oversee its rollout and set targets and agree off-track remedial action [8, 9]. The 
SILC project team was assembled in 2016, consisting of academics and clinicians 
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with extensive experience in the field of talking therapies and service design [9]. 
This team was responsible for developing learning resources, providing mentorship 
support and tracking data through the relevant quarterly themes of service devel-
opment. The team also worked directly with individual service leads to cascade 
learning and implement practice change, compiling routine reflective case notes 
and disseminating learning throughout the network.
A series of prospective pilot services were approached and recruited in early 
2017, subject to expressions of interest and eligibility criteria. The SILC initiative 
was specifically aimed at mental health care TSOs using CORE IMS computerised 
quality evaluation systems [17] to obtain evidence on their delivery and strengthen 
their position for funding and benchmarking. Those eligible had been using CORE 
outcome measurement systems for over 5 years, primarily as an administrative tool 
to log clinical activity. Within all but one TSO expressing interest, there was little 
analysis of the data being undertaken, and no indication of it being used clini-
cally or to enhance service quality. Prospective services were using traditional pre 
and post-therapy measurement approaches, acquiring outcomes data for around 
40–50% of clients; a rate which is representative of the field and this methodology 
generally [18]. Many were also experiencing high rates of non-attendance and attri-
tion, plus modest clinical outcomes for those with outcomes data.
The exploration phase of Aarons, Hurlburt and Horwitz [11] conceptual model 
for implementation identifies the importance of inner and outer contexts. In this 
project, it seems early withdrawal during the recruitment stages was due to a com-
bination of socio-political factors and lack of absorptive capacity which impeded 
progress [11]. What had started as 12 prospective members soon halved to only six. 
Various reasons were given but discontinuation was mostly cited as being due to 
managerial turnover, lack of capacity for change, and workforce restructuring, or 
resistance. By contrast, the remaining TSOs demonstrated their levels of commit-
ment via an initial attitudinal survey which, when disseminated to all practitioners 
(n = 49), achieved a high response rate of around 80%.
The six services joining the project ranged in size, geographical location and 
clinical specialism. Annual throughput ranged from around 80–300 clients per 
organisation. Clinical support specialisms included psychological support for 
female victims of domestic abuse; women on low incomes; parenting; unpaid 
carers; and general counselling support. Informed by QIF support strategies, each 
service was assigned a mentor from the SILC project team using a consultation and 
matching process [8, 9]. Members received regular updates via a monthly blog post 
on the project’s website (www.silcuk.org) and a quarterly newsletter via email. 
Resources were shared via the website and there were opportunities to contribute in 
online discussion forums. The combination of online meeting platforms and email 
correspondence enhanced the sharing of stories, communicating learning and 
progress, and helped to sustain the network.
Figure 1. 
The SILC CLN model, adapted from the IHI [10] ‘breakthrough series’ collaborative model.
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2.3 Plot
Expanding on the story structure framework, this section will incorporate a 
generic narrative mountain structure, breaking down the plot by its background, 
rising action, climax, falling action, and resolution.
2.3.1 Background
During each quarter, the project team worked with each TSO to produce an 
implementation plan including a set of targets, infographics, quality checklists, 
report templates and mentorship support, with PDSA cycles to structure the 
process [8–10]. Many of these tools required regular, in-depth auditing of data 
recorded during assessment, treatment, and discharge. Analyses were comple-
mented by attitudinal surveys to front-line practitioners focusing on their percep-
tions and experiences across each quarter. Services were encouraged to reflect and 
communicate their learning at the quarterly residential meetings, while critically 
appraising fellow member’s contributions.
2.3.2 Rising action: Events leading up to the main challenge(s)
Throughout the project, it became clear that an organisation’s success in address-
ing the challenges depended on their relationship with the process of using mea-
surement questionnaires and how deeply practitioners and clients were engaged 
in responding to feedback. The team later conceptualised this as a development 
cycle with four distinct evolutionary stages that described the operational depth of 
practitioners’ relationship with measurement: Pre and post-therapy measurement 
using paper forms; measurement at every session using paper forms; digital mea-
surement at every session using tablets or computers; and digital measurement at 
every session tracking and sharing outcome progress directly with clients throughout 
Figure 2. 
The evolutionary stages of measurement within SILC TSOs illustrating the development cycle and value to 
stakeholders.
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the entire therapeutic encounter. It was recognised that services which were further 
along in this cycle had an inverse relationship with measurement in terms of its input 
and value towards stakeholders. Those in the later stages were able to maximise the 
value for clients that in turn benefitted other groups including practitioners, service 
management, and boards/funders. Conversely, those operating in the earlier stages 
were limited in their value to certain groups, typically to the boards/funders. Figure 2  
shows a conceptual model of this, including the resulting value for stakeholders.
Conceptual implementation models highlight how the structures and processes 
that exist within organisations have an influence on the adoption of practice changes 
during the active implementation phases [8, 10, 11]. Within the SILC project, it was 
observed that completing paper forms, particularly at every session, generated huge 
administrative and inefficient burdens for members. This created barriers for practi-
tioners looking to use data as feedback to enhance client outcomes and develop their 
clinical skills. During the year, most organisations evolved their administrative pro-
cesses by replacing paper with digital methods, recording via electronic tablets. The 
services most successful in achieving the optimal rates for each quarterly challenge 
described understanding measurement as a construct and extension of the client. 
By focusing on creating the maximum value of measurement for clients, a myriad of 
other benefits at different stakeholder levels was also reported [19]. Naturally, some 
services were more equipped than others in accessing the appropriate technologies.
2.3.3 Climax: The main challenge(s) reach a high point
During the project, one of the participating TSOs withdrew due to a turnover 
in management and evolving financial pressures. Two other services experienced 
management turnover during the project which, although not impacting on their 
participation, did require additional input and training from the SILC project team. 
Practitioner turnover was understood to be common in TSOs [2–4], however, the 
rate of turnover concentrated at a managerial level had not been anticipated. For 
services with a complex management structure, this too complicated the sharing 
of learning and addressing each quarterly challenge. It was discovered that when 
managers with an on-hand leadership style were absent, this would impact on key 
aspects of their service operation, including the collection of high-quality data.
Another key challenge regarded the issue of session attendance and unplanned 
endings. A list of categorical reasons for why a session was not attended was com-
piled to record each time this occurred. Although the reasons recorded for cancel-
lations were high, this was not the case for those who did not attend (DNA) (no 
advanced warning given) despite subsequent sessions being attended in approxi-
mately half of all instances. The most common reason for cancellations during the 
second quarter (n = 482) was ‘Health Problems’ (40%) while for DNAs (n = 160) it 
was ‘Unknown’ or ‘Not Recorded’ (76%). The absence of reasons recorded despite 
sessions being subsequently attended suggests practitioners either forgot or did not 
feel comfortable exploring why a session had been missed. This is concerning as 
DNAs were found to be indicative of an unplanned ending.
Definitions are important and have shown to vary the reported unplanned 
ending rate [20]. During the project, the unplanned ending rate reduced from 32% 
at baseline to 27% at the end of the third quarter, however defining and interpret-
ing these rates revealed notable issues. Among the participating members, there 
were multiple interpretations about what constituted a planned versus unplanned 
ending. Given its inherently subjective nature and potentially negative connota-
tions, this limited the analysis somewhat. However, the links between session non-
attendance and unplanned endings were consistent across all services and tended to 
occur early in treatment, as described in the next section.
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2.3.4 Falling action: The characters work towards resolving the main challenge(s)
One of the aims of the SILC project was to provide services with regular analyses 
to inform delivery and operation. This section reports on some of the headline find-
ings along with extract quotes from two of the SILC TSOs. Systems-level modelling 
demonstrates the importance of considering the interrelationships between indi-
vidual practice elements as opposed to solely focusing on each in isolation [11, 21]. 
Although the challenges during each quarter were distinct, the areas of overlap were 
noteworthy. Not only was session non-attendance linked with unplanned endings, 
but those TSOs with the longest standing commitment to high-quality data also 
reported the highest rates of clinical improvement.
2.3.4.1 Data quality
One major shift during the first quarter was to adopt sessional ROM, moving 
from traditional pre and post-therapy measurement approaches. This process was 
supported by a dedicated project member auditing and feeding back information 
to services. By the end of the first quarter, pre-and-post outcome completion rates 
increased from an average of 65% at baseline to 98%, while by the end of the year, 
this was 97%, with all TSOs achieving above 90% and half achieving 100% comple-
tion rates (Figure 3). These values were almost identical to the IAPT programme’s 
recent achievement of 98%, a decade after its first site implementation [7].
2.3.4.2 Session non-attendance
At the start of the second quarter, members began to record session non-
attendance, including when an appointment was cancelled (by client) or the client 
DNA (no advanced warning given). One of the primary areas of interest was 
understood when sessions being missed were most likely to occur. Aggregating 
each service’s datasets, the total number of appointments per sequential session 
number was tallied to assess what proportion was recorded as either cancelled 
or DNA. Including only session numbers with over 10 appointments each, it was 
possible to chart this data (Figure 4). It was identified that cancellations as a 
Figure 3. 
Improvement of pre-and-post outcome measures completion rates for all SILC TSOs, 1 year before-and-after 
the project.
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proportion tended to increase the longer therapy progressed; although this might 
be due to a lower number of appointments at these stages. DNAs as a proportion 
did not exceed 10% for any session number although they did tend to occur earlier 
in therapy, with sessions 2–5 reporting the highest rates of 7–8%. The occurrence 
of DNAs declined somewhat as therapy progressed, possibly due to contract-
ing which discharged clients after missed appointments without prior notice. 
Focusing on session non-attendance helped determine the scale of the challenge 
and how the pattern of cancellations and DNAs differed, prompting two par-
ticipating services to a revise their policy in the interests of equitable access and 
service efficiency.
2.3.4.3 Unplanned endings
For the third quarter, the focus shifted to exploring the nature of unplanned 
endings. An analysis was undertaken to explore the potential associations between 
unplanned endings and the rate of non-attendance during therapy. This analysis 
found that, across all services, there was a link between session absence and ulti-
mate attrition, especially regarding DNAs. For all TSOs, the DNA rate for clients 
with an unplanned (13%) versus planned (2%) ending was around 6½ times 
difference, ranging from 2 to 18 times across providers (Figure 5). By the end of the 
third quarter, those with planned endings attended almost 3 times more sessions 
(11) than those with unplanned endings (4) and were more likely to report reliable 
improvement for planned (62%, n = 226) versus unplanned (36%, n = 70) endings.
To assess how the pattern of non-attendance varied during therapy per ending 
type, session numbers and total appointments recorded were banded across all ser-
vices (Figure 6). This analysis found that again, non-attendance was indicative of an 
unplanned ending, with higher rates of cancellations and DNAs. For those with an 
unplanned ending, it also revealed that while DNAs as a proportion were reduced in 
the lower session number bandings (2–4; 5%), they remained consistent at around 
17–21%, excluding the 14–16 banding which reported a rate of 30%. Similar to the 
overall patterns of attendance, cancellations as a proportion of all appointments 
tended to increase the longer therapy progressed but again, this could be explained 
by a decrease in appointments recorded during these later subgroup stages.
Figure 4. 
The rate of appointment non-attendance per session number showing a higher proportion of DNAs earlier and 
cancellations later in therapy, across all SILC TSOs.
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2.3.4.4 Clinical outcomes
In the final quarter, the project focused on clinical outcomes and understanding 
therapist variation and trajectories of change. To identify a possible dose-effect, an 
analysis was undertaken to assess the rates of change across individual domains of 
the CORE-OM (wellbeing, problems, functioning, and risk) within the one service 
using the full 34-item measure, as opposed to the shorter CORE-10 which does 
not record all domains [17]. A pattern of average scores were mapped relative to 
individual session numbers up to the 10th session (for clients having 10+ appoint-
ments each) for those who reported reliable improvement (n = 130; 891 sessions) 
versus those who reported no reliable change (n = 39 clients; 243 sessions) or 
reliable deterioration (n = 7 clients; 53 sessions) (Figure 7). Based on this analysis, 
most of the score changes tended to occur early in treatment for those reporting 
reliable improvement, with an average decrease in scores of −6.1 across the first 
four sessions, remaining steady between sessions four to seven (−0.5), and then 
Figure 5. 
A comparison of session non-attendance reporting a higher rate for unplanned versus planned endings across 
all SILC TSOs.
Figure 6. 
A comparison of session non-attendance bandings showing a steady DNA rate and increasing cancellations for 
unplanned versus planned endings, across all SILC TSOs.
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decreasing steadily from sessions seven to 10 (−2.3). For those reporting no reliable 
change or reliable deterioration, scores generally remained steady, with average 
changes ranging from 0.2 to 1.7. This suggests the first four sessions were important 
for identifying clients who were likely to improve or not. This triggered the integra-
tion of a flag feature to remind practitioners to review progress early in therapy to 
identify those at-risk of showing no change to provide additional support.
2.3.4.5 The lived experiences of two TSOs engaging in the SILC project
Informed by the QIF, improvement for future applications requires learning 
from experience [8]. To gauge the experiences of those participating in the project, 
a brief semi-structured interview was conducted at the end of the year to explore 
what service managers thought of the initiative, and how they might improve it for 
future services embarking on a similar journey of collaborative learning. The boxes 
below contain extracts from these interviews with two self-selected TSOs.
Figure 7. 
A pattern-of-change comparison across the CORE-OM per session number illustrating early improvements for 
clients reporting reliable improvement compared with no reliable change or reliable deterioration.
Service A: Interview Extracts
Our first question was how is it going to work for our clients? Building that value for them, and the practitioners, 
giving them a value to the work. This is not a measurement, it’s not an outcome, it’s an aide to the process, something 
that helps the work with clients. And then, once we all understood that, we could have an open conversation about 
why we might want something like this. You really need that opportunity to embed it early on though.
It completely allowed us to cement and consolidate how we work. I mean the data the project provided, really 
cemented what we were doing, how we were doing, we were using data in the right way, but it also gave us ways to 
look at data differently, what we could do, so it was an enhancing experience. That allowed us to feel quite proud of 
what we do, and have it validated, which for us a charity tucked away from others, that was a nice thing to have it 
validated on that level.
I did that like kind of cyclical journey, that it’s not linear, we’ve got new practitioners all the time, we’ve just got 8 
new practitioners in now, and they’re going back through that loop. They’re doing their first data clean this week 
where I’m just putting them through all the information, right we need to go through and see, right this is done, this 
is done, and you keep on embedding it, keeping the data quality up really. Constant, it must be really because when 
I’ve dipped out of the service, it went a little bit, my practitioners got a little bit complacent.
I think one of the biggest things for us, the 4-session thing, spotting that. We actively use that in supervision now, so 
it’s really looking at, from that first session, you can see it quite clearly. So, there’s more focus in those first 4 sessions, 
really looking at what the client needs, with a view to contracting through goals, further through that process. So that 
we’re really meeting those needs, making that environment that’s conducive then to achieving good outcomes.
We’re about sharing good practice, we’re about empowerment, we’re about creating choice and all those things. Being 
part of SILC fitted with part of the ethos so it was nice to go and be there in that capacity with other services. There’s 
something about talking to someone who’s been through it, we’re just through it. It’s that kind of picking their brains 
and have you thought this?
For me it’s about credentialing the sector, it’s about professionalism, it’s about best practice, it’s about evidence base, 
not being afraid to strive, to get to those levels, and get good outcomes and be accountable for that. I don’t think 
therapy is any different from if you go to a shop to buy something you expect it to be good quality. I don’t see why in 
therapy, clients shouldn’t expect it to be any different.
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2.3.5 Resolution: How things have ended up in this story
In keeping with the IHI’s [10] collaborative learning model framework, the 
first year of the SILC project culminated in a summative conference. Nearly 100 
delegates were in attendance, each representing a range of different sectors within 
the field of talking therapies. Both the project team and self-selected SILC TSOs 
held a discussion regarding their experiential learning during the first year of the 
project. There was a consensus at the event about the operational challenges facing 
modern-day talking therapy services. While systems were becoming increasingly 
sophisticated, the training and support necessary to build in-house expertise were 
reportedly difficult to access due to time and resource constraints, a saturated and 
uncertain field, and isolated working practices. Providers, particularly in the third-
sector, desired the opportunity to work in partnership with others to share learning 
and enhance theirs and the sector’s organisational and therapeutic models further.
With the first stage complete, the SILC project has amassed a wealth of learning 
which will be converted into a modular learning programme, providing a resource 
for future applications of the network [8, 9]. This will replicate the CLN model and 
invite existing SILC members to act as guest speakers and offer unique support 
and valuable insights to newly recruited collaborative members. There are three 
existing SILC TSOs who have declared their interest and commitment to continuing 
with the project. Due to a turnover in management and decrease in contribution, 
two members have since withdrawn. The next phase of the initiative will focus on 
expanding the network, building on the existing knowledge and aggregate data to 
support ongoing analyses and resource development.
2.4 Themes
Themes are the essence of a story, the central constructs which reflect the 
actions, perceptions and experiences of the characters in their situational contexts. 
They represent the underlying ‘big ideas’ which transcend the distinctions between 
Service E: Interview Extracts
Having the support from the team that was specific to our service, having experts on hand when you needed them. 
Keeping on top of the data quality is not as easy without the help of the project team, and our monthly calls and the 
little tool pointing out the problems… Whereas sitting down and finding the problems myself is another matter.
I personally enjoy getting involved in things like this. I find it very stimulating. It ticked a lot of boxes for me, in terms 
of what we wanted for the service, but also for me personally, it was an interest. You couldn’t have designed it better 
for me… So, I think without that personal interest and enthusiasm it wouldn’t have happened.
I think I’m very fortunate in that I’ve got a very good group of people, I think credit needs to go where it's due, they 
are a group of people who are motivated and supportive and I think all we did was talk about, well this is going to 
be a benefit to the service, and they’re all very committed to the service and they came, I suppose, with open minds.
That’s been one of the key things for me, has been the experience of being part of the learning collaborative. And I 
think that is so valuable, personally and also for the service, because you’re going through a journey with other services, 
their journey’s different but there are similar issues. It’s just that ability to share learning and connect with people who 
have a similar job, are having similar issues. When you have something, and they say, yeah that’s happened to me. 
And for me, it takes away that sense of being in your own little bubble, in your own little service, which I wouldn’t say 
is isolating but that you’re not part of anything else. The learning collaborative made you feel part of something bigger 
with some connections, and yeah, doing the same thing you’re doing, I thought it’s fabulous, it’s brilliant.
It’s the practical stuff, we’ve become a service that does sessional measurement using tablets, that’s the way we do 
things now. We’ve changed the way we manage DNAs, we have an appreciation of data quality, and that’s not just 
me, the team come along and say why haven’t I got 100%? Why is this only saying 90%? Can we have a look where 
that 10% has gone? So, there is an appreciation now of the importance of good data. In fact, the things that SILC 
was meant to address, are the things that have changed in our service.
It’s a no-brainer. Why wouldn’t you? I can’t see any reason why you wouldn’t, unless you haven’t got the support to 
see it through. Know your organisation, know that you’ve got that support, to be able to put the time into it, those are 
the two caveats, otherwise, it’s a no-brainer.
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settings and circumstances and help conceptualise elements and links between 
them. This is important given the lack of guiding conceptual models for the sustain-
ment phase of implementation [11]. Listed below is a discussion on some of the key 
themes both the participating services and project team uncovered during this stage 
of the project.
2.4.1 The possibilities of CLNs in mental health TSOs
The unintegrated nature of TSOs in the UK means there can be obstructions to 
developing and integrating EBP [2–4]. Within the field of talking therapies, deter-
mining what constitutes as EBP has been criticised for its reliance on controlled 
study methodologies which, due to their somewhat artificial nature, are considered 
detached from the clinical realities of routine practice settings [22, 23]. Certain 
advocates support a PBE approach to complement and address these limitations 
[24]. However, PBE relies on the collection of robust, aggregate datasets across 
multiple organisations sharing a common system or model.
Fragmentation, isolated working practices, and resource constraints can limit 
TSOs generating the PBE necessary to support their delivery [2–4]. Indeed, the 
primary interest from prospective members in this project was overcoming these 
barriers and demonstrating they were treating clients effectively. By pooling experi-
ence, resources and expertise around a central, unifying theme, TSOs were able to 
systematically explore, assess, understand and reflect upon key aspects of service 
quality development. Through iterative cycles, strategic improvement models and 
coordinated and collaborative dialogue [10], services were able to generate timely 
and actionable insights that were relevant to their unique circumstances. Testing 
practice changes on small scales, using focused inquiry and PDSA cycles, helped 
achieve small wins which, according to evaluation theories, can be an effective 
strategy for boosting perceived capabilities [6, 10].
Replicating previous research findings [2, 3], access to a supportive academic 
project team was deemed invaluable for producing, mentoring and synthesising 
analyses and learning across the network. However, liaising with several TSOs 
proved to be a lengthier and more complicated process than first envisaged; an 
experience which is echoed elsewhere [6]. This identifies an important obstacle for 
sustaining CLNs, particularly those undertaking continuous analyses. It might be 
that by offsetting resources to a project team, this creates a more efficient process 
within individual services as it shares the expertise around a common need. If this 
were true, then it could prove more efficient and cost-effective for TSOs overall.
Given the central communicative nature of CLNs, it is important these channels 
are equitable. Within the third-sector, organisations tend to differ in size and can be 
equally varied in their operational modelling [2, 3]. This inequity in size and visibil-
ity could feasibly leverage greater influence over smaller providers to work towards 
their agenda. To overcome the challenges of distinct delivery models within CLNs, 
a central governing platform using cooperative representation could therefore be 
valuable for identifying topics of interests and establishing a dictionary of terms. 
Similarly, these communication channels ought to use terminology that is consistent 
and agreed upon, particularly around subjective concepts such as ending types as 
doing so would ensure greater validity and reliability in data analytics [20].
2.4.2 Management and leadership
Many implementation frameworks emphasise the planning stages as critical 
to successfully embedding innovation [8, 11–13]. Because implementation can be 
a complex process involving integrating existing practices with new, it typically 
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requires a well-planned, structured and iterative process, addressing the vari-
ous philosophical and practical barriers that can occur regularly [9, 15, 21]. It is 
within these contexts that supportive leadership can be a facilitating factor  
[2, 11, 15, 21, 25]. Without effective leadership to track, monitor and effectively 
champion the merging of practices, any expended effort can unravel [9, 15, 25]. 
Those in leadership positions need to be present and well-respected, retaining 
a detailed awareness and understanding of delivery and operation [15]. Service 
quality development through CLNs therefore appears to be reliant on manage-
ment structures and local leadership.
In considering the scale of change and level of turnover in TSOs, particularly 
at a managerial level, the reliance on leadership highlights a notable barrier. 
Given the project team tended to work exclusively through managers brokering 
knowledge and training, their absence ultimately affected their organisation’s 
participation and operational processes. It could be argued this was a side-
effect of the chosen methodology which may have benefitted from a broader 
involvement and contribution among the workforce. Advocates across the field 
recommend ensuring a local champion is permanently in place, advising that 
those departing a service provide sufficient training to those replacing them 
[9, 15, 26]. While this recommendation is practical, how it applies to TSOs is 
perhaps more complicated.
Continually nurturing the operational climate through sustained involvement 
and being present can help resolve the functional mechanisms of feedback systems 
[15, 25–28]. A perceived lack of presence in the project among some practitioners 
served to undermine the initial enthusiasm and positive ethos established at the 
project’s outset. Services which thrived tended to dedicate additional time and 
resources to sharing information in an open and accessible manner. This actively 
engaged the workforce in the minutiae of feedback informed treatment (FIT) [28] 
and encouraged more open dialogue. The literature on FIT teaches the value of 
routinely soliciting responses from clients about treatment progress, aiding practi-
tioners at a therapeutic level [28–30]. However, there is an additional service-level 
which could also help inform practitioners and other stakeholders about enhanc-
ing client engagement and outcomes. By combining a FIT model with a feedback 
informed service, practitioners could have timely access to relevant learning. With 
reference to the QIF [8], supportive feedback mechanisms will be relevant to all 
stakeholder levels and through aggregate data, the client voice can be made acces-
sible to all, helping sustain innovation.
2.4.3 The resource challenge of TSOs
Based on the learning from this initiative and relevant national and international 
research [2–4], there appears to be a significant resource challenge facing TSOs. 
Although many report having an interest in quality improvement [3], the con-
straints on providers including turnover, financial pressures and limited budgets, 
appear to greatly impact their ability to generate data and engage in practice 
development [2–4]. For a sector that relies heavily on volunteers, some of whom are 
in trainee positions [1], preserving a level of local expertise represents a continual 
challenge, particularly as systems become more expansive, specialised and costly. 
Although the CLN was a means to pool and share resources, supporting the imple-
mentation phase [11], external pressures had a notable influence on its integration, 
process and overall output. The level of attrition at the beginning and eventual 
withdrawal of others highlights the scale of this challenge. Consequently, this 
further demonstrates the criticality of the QIF phases in thoroughly assessing the fit 
between the host setting’s aspirations and readiness for change [8, 9].
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Given the sheer scale of change and advancing pace of new technologies, 
feedback systems and innovations are becoming increasingly sophisticated 
while at the same time, access to training and support might not be keeping 
pace [3, 31]. For many, including attendees at the summative conference and 
across the wider literature [3], allocating resources to this endeavour might be 
considered non-feasible as few can afford or justify it economically. This issue 
is further compounded by the fluctuating and isolated nature of services as 
well as barriers in accessing the literature due to subscription paywalls [2, 3]. 
Accordingly, this highlights the need to consider the additional training and 
support required when adopting new innovations.
Despite its limitations, a CLN could address some of the resource challenges 
identified, increasing the opportunities for learning. Disseminating feedback 
throughout a network might help overcome some of the barriers to accessing 
research and forming partnerships [5, 6, 10]. Shared learning across all levels of the 
network, could foster a broader culture of openness and training, supporting col-
laboration across multiple platforms, while also generating an asset for feeding back 
insights across the sector. Undoubtedly, this would rely on the aggregation of robust 
datasets and communication platform to support this process [5].
2.4.4 Designing the infrastructure
The experiences from this project revealed the influence of organisational 
factors and infrastructure on the uptake of practice changes. Although research 
on the integration of feedback systems and ROM have identified numerous practi-
cal barriers, much of the emphasis has focused on practitioners [9, 15, 31–37]. 
Indeed, positive attitudes towards feedback have been shown to facilitate the 
effect on clinical outcomes improvement, while resistance can have the opposite 
effect [33, 38–40]. Resistance reportedly stems underlying performance anxiety 
or negativity about the relevance and utility of the practice [9, 15]. However, the 
learning from this project highlights how positivity and motivation might not be 
sufficient in isolation.
Despite the generally positive attitudes from the survey and among the 
management mentees, itself likely a result of the selection process, many TSOs 
still encountered challenges, many of which appeared to be due to limitations in 
the infrastructure and frustrations with the technology. This, in turn, affected 
their capacity to use the system, something which is shown to be a facilitator in 
implementing EBP [25, 27, 31]. Restrictive and frustrated working practices can 
lead to negative perceptions forming [25, 27, 36, 41], suggesting attitudes might be 
mediated by how user-friendly and engaging a system is. For TSOs facing time and 
resource constraints, the simplicity of a feedback system is perhaps more pivotal. In 
these circumstances, systems may benefit from a uniform, standardised approach 
so that training and support can be refined and accessible via fully integrated and 
self-led instructional packages [32]. In terms of the QIF [8], the critical steps for 
assessing the needs and resources, capacity, and pre-implementation training 
would benefit from accessible resources which are intuitive and easy to understand.
2.4.5 Refocusing measurement to respond and maximise the value to clients
Traditionally, measurement in TSOs have been undertaken to satisfy the needs 
of boards and funders and to a lesser extent, service managers [3, 4]. The pressures 
on services have meant that pre and post-measurement approaches have dominated, 
with its purpose serving mainly administrative rather than clinical needs [3, 9]. 
ROM established a method for improving data quality and representativeness, 
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although the emphasis regarding its clinical utility or use in service development 
has only recently been advanced [7]. This illustrates how the focus and value of 
measurement have been positioned to satisfy a broader sector-level drive. However, 
by framing measurement in a way to maximise the value for clients, as observed in 
this project, there appear to be many cumulative gains for all stakeholders, including 
practitioners, service managers and boards/funders.
Across each of the common challenges, there seemed to be a critical period, 
usually within the first four to six sessions, which correlated with eventual out-
come. For instance, a large proportion of DNAs tended to occur early in treatment 
which were a useful indicator of an unplanned ending, and by extension, a reduced 
chance of reliable improvement [20]. For clients reporting reliable improvement in 
one TSO, most change seemed to occur during the first four sessions, while those 
reporting no reliable change or reliable deterioration showed little change across 
a 10-session period. This emulates the wider literature which identifies the initial 
stages as being a useful indicator for a client’s subsequent engagement and outcome 
[42–45]. Accordingly, this trend highlights the criticality of early engagement and 
warrants a further discussion about the implications of keeping clients involved in 
therapy who report no change or attend infrequently. Evidence has shown that deci-
sions to prolong or conclude therapy despite a lack of positive therapeutic change 
can be influenced by subjective beliefs, norms and attitudes, sometimes supersed-
ing what feedback monitoring and practice guidelines recommend [45].
According to the literature, the clinical benefit of measurement can be mediated 
by a practitioner’s engagement and attitude towards outcomes monitoring [33, 38, 39]. 
Moreover, timely access to feedback has been shown to be a critical factor in the use of 
data among practitioners [27, 34, 36, 46]. TSOs which encourage open dialogue and 
pay greater attention to this information could produce cumulative benefits in each 
of the quarterly themes identified [10, 30, 47]. An organisational culture of openness 
and commitment to learning was important and replicates findings reported else-
where [15, 46]. Additionally, giving practitioners access to service-level data might 
assist them in overcoming residual ambivalence because its application to service 
quality development is readily observable.
2.4.6 Recommendations
For those interested in implementing a CLN to support TSOs, there are several 
recommendations based on this project’s findings. Firstly, recording high-quality 
data is crucial to this model. Securing high-quality data helps support the network 
and aggregate learning by effectively threading the client voice throughout all 
stakeholder levels. Promoting client engagement in the process of measurement is 
an effective strategy for enhancing data quality and building the opportunities for 
clinical application [9, 31, 47]. Because of this, it is important that implementation 
teams do not underestimate the infrastructure necessary to support practitioners 
working to deliver these innovations [15, 32, 35, 46]. While pooling resources can 
help overcome challenges relating to cost and access to expertise, without a shared 
framework and understanding of the key concepts, a CLN and its associated 
analyses are likely to be impacted. In keeping with the wider literature, access to 
expertise and committed project team can be beneficial for supporting the net-
work [2, 3, 5, 6, 9]. Focusing on distinct areas of service delivery through iterative 
improvement cycles and acknowledging their interdependency can help achieve 
cumulative benefits through the combination of smaller gains [6, 21, 25]. For 
TSOs, the role of leadership and effects of turnover cannot be understated. While 
it might not be feasible in TSOs to ensure a local champion is always in place, it is 
valuable to build a system that enables receptiveness towards continual practice 
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innovation. A broader involvement and contribution among the workforce 
through wider supportive feedback mechanisms represents one effective strategy 
to overcome this.
3. Conclusion
TSOs represent a valuable and growing player in the provision of mental health 
care, yet many are constrained by limited budgets, isolated working practices, 
and a constantly shifting workforce. Together, these make producing and access-
ing evidence difficult, further limiting the sector from credentialing their impact 
and engaging in service development. To overcome these challenges, a CLN was 
implemented involving six TSOs and a dedicated project team to share learning 
and resources with the aim of improving delivery and operation in the areas of data 
quality, session attendance, unplanned endings and clinical outcomes. The CLN was 
inspired by the IHI collaborative model [10] framework for integrating and test-
ing improvements using PDSA cycles and the implementation process was guided 
by the QIF [8]. It was found that introducing ROM substantially improved data 
quality which acted as the bedrock for all subsequent analyses and discussion. There 
appeared to be strong links between each of the common challenges, including 
increased non-attendance being associated with the occurrence of an unplanned 
ending, itself linked with a lower chance of reliable improvement. Overall, this 
approach to generating timely and relevant practice-based insight through partner-
ship working and mentorship support proved to be effective for stimulating service 
quality enhancement. Although TSOs face many unique challenges, including high 
staff turnover and strained budgets, those with on-hand and inspirational leader-
ship and commitment towards maximising the value of measurement for clients 
reported most success.
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Abstract
Idai was a strong tropical cyclone in Central Mozambique, causing over 1000 
deaths, destroying schools, hospitals, roads, and more than 239,731 houses, displac-
ing thousands of people to 136 accommodation sites, and leaving people in need 
for assistance. The resulting precarious hygienic conditions caused outbreaks of 
diseases such as malaria and cholera. This communication summarizes the onset of 
cholera outbreak in Sofala province and its response. It was declared on 27 March, 
and the number of cases raised up to 6766 and 8 confirmed deaths, with the highest 
incidence in the city of Beira. The government and partners made integrated efforts 
to control the disease, establishing treatment centers and units and improving 
sanitation and hygiene and surveillance. Furthermore, 800,000 people were 
immunized, and the results seemed satisfactory considering the response. Although 
cyclones are rare, Mozambique has a very limited capacity to handle their impact, 
and this urges the country to keep a contingency fund for future disasters.
Keywords: cholera, Cyclone Idai, Sofala, Center of Mozambique, outbreak
1. Introduction
In mid-March 2019, Tropical Cyclone Idai from category 4 hit Mozambique, dev-
astating the port city of Beira and surrounding areas, following torrential rains and 
strong winds, causing massive flooding and leaving entire communities submerged 
[1–3]. It has damaged supplies, cut off clean water and sanitary facilities, and 
destroyed different infrastructures including schools, hospitals, houses (239,731), 
roads, rails, disrupting regional trade, and supplies of fuel, wheat, medicines, and 
other goods, even from neighbor countries such as Zimbabwe and Malawi [3–5].
Thousands of displaced people were sheltering in 136 accommodation sites, 
including schools, across Sofala, Manica, Zambezia, and Tete, as reported by the 
National Institute of Disaster Management (INGC) [4, 6, 7].
Idai caused a range of public health consequences, including mortality (598 
confirmed deaths until 02 April 2019), injury, and infections [8, 9] due to water-
borne and vector-borne diseases including cholera, malaria, and measles, and more 
than half of affected people are children [2, 10, 11]. Two weeks after Cyclone Idai’s 
landfall, the index of cholera was confirmed in Mozambique with the death of five 
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people. After the Ministry of Health declared a cholera outbreak on 27 March, 4979 
cases and six deaths were confirmed [1, 3, 5, 8, 12].
Cholera is an acute, secretory diarrhea caused by strains of the Gram-negative bac-
terium Vibrio cholerae that occurs in both endemic and epidemic patterns, presenting 
symptoms like watery diarrhea, rice-water stools, fishy odor to stools, vomiting, rapid 
heart rate, loss of skin elasticity, dry mucous membranes, and low blood pressure. This 
bacterium is usually found in food or water contaminated by stools from a person with 
the infection, and, if untreated, the fatality rate can be as high as 30–50%, but with 
rehydration and electrolyte replacement, the death rate decrease to 1% [8, 13].
Environmental factors play an important role in the epidemiology of cholera. 
The flooding and displacement of people has increased the risk of cholera because 
many of them spent days without accessing safe water supplies, resorting to drink 
the floodwaters. There are some videos of children playing with the same water that 
unfortunately were strewn bodies of humans and animals. Beyond that, menstru-
ated women are also susceptible to waterborne diseases due to the use of unsafe 
water to wash their clothes, during the bath or while collecting water to prepare 
food [1, 8, 14–16].
Idai survivors received supplies to purify their drinking water, food supplies, 
and items such as soap, nappies, towels, and blankets, to stop spreading cholera. 
The Mozambican Ministry of Health (MISAU), World Health Organization 
(WHO), Cooperative for Assistance and Relief Everywhere (CARE), and other 
NGOs worked in setting up treatment centers and clinics, as well as helping to run a 
massive campaign, where 800,000 doses of oral cholera vaccines were distributed 
and dispensed [2, 4, 10]. This paper aims to summarize the status of the outbreak of 
cholera in Mozambique due to the deadliest storm Cyclone Idai.
2. Sources and documentary analysis
This short communication was based on simple reviews of the most relevant 
literature related to the cholera outbreak as a result of Cyclone Idai. The documen-
tary analysis was performed through ATLAS.ti (ATLAS.ti GmbH, Berlin, Germany) 
and partly in Microsoft Excel™ (Microsoft, Redmond, Washington, USA) and 
mainly based on flash updates by the United Nations Office for the Coordination 
of Humanitarian Affairs (OCHA), WHO, UNICEF, OXFAM, Health Cluster of 
Mozambique, and other agencies.
3. Overview of Cyclone Idai
Due to the damages caused by Cyclone Idai, it is important to know that dif-
ferent humanitarian helps were given, coming from national and international 
entities, both to the outbreak of cholera and to other diseases, in order to reduce the 
impact caused to the cyclone victims.
The central region of Mozambique was affected by heavy rains since 6 March 
2019. It was a system formed in the Mozambican channel, which evolved from 
tropical depression to moderate tropical storm called Idai that took more than 800 
lives and displaced thousands of individuals [17].
The house’s destruction, roads, hospitals, clean water, and sanitary facilities also 
puts the traveler’s health at risk, so they should always take the basic prevention, 
such as drinking and using safe water, washing hands often with soap, avoiding 
bug bites and direct contact with contaminated floodwater, or avoiding travels to 
dangerous areas [18, 19].
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Idai was one of the worst tropical cyclones on record to affect Africa and the 
southern hemisphere and caused catastrophic flooding, landslides, and large numbers 
of causalities in Mozambique, Zimbabwe, and Malawi, affecting more than 3 million 
people, but the most affected area was Beira, Mozambique’s second largest port city, 
where the cyclone’s landfall was on 14 March [17]. The heavy rains, strong winds, and 
severe flooding caused problems with water and food supplies, sanitation, electricity, 
transportation, shelter, communication, security, medical care, and mosquito con-
trol, creating opportunities for outbreak diseases, such as cholera. Due to the disasters 
caused by Idai, 6766 cholera and 43,556 malaria cases were registered [1, 19–21].
Idai affected 1,85M people (more than half were children), displacing 90,000 to 
136 accommodation sites, mostly schools and churches. The sheltered people were 
sleeping in open spaces, increasing the risks of gender-based violence [11].
Tropical Cyclone Idai was outside the range expectations for a typical tropical 
cyclone that has happened in Mozambique and its neighboring countries. More 
than 14 countries provided supplies to help the affected areas. The United Nation’s 
Central Emergency Response Fund (CERF) launched an emergency appeal for 
US $282 million to respond to cyclone, which affected Mozambique, Malawi, and 
Zimbabwe. Furthermore, goods and military or rescue planes, helicopters, ships, 
and boats were provided to aid the huge search and rescue effort needed. Only 17% 
of the total amount required had been funded [3, 10, 22].
3.1 Area of impact
The most impacted area includes the city of Beira, in the center of Mozambique, 
province of Sofala (Figure 1). Sofala is a vast province composed of 12 districts 
located in central-eastern Mozambique with a total area of 68,018 square kilome-
ters and population of 28,861,863 individuals (2017 census). It is bordered to the 
Figure 1. 
Draft of Mozambican map showing the affected areas by Cyclone Idai in Sofala province. Source: Dauphin and 
Stevens [23], under public domain.
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north by Tete province, to the northeast by Zambezia province, to the south by 
Inhambane province, and to the west by Manica province.
4. The outbreak of cholera
A high number of cases of cholera were reported in April 2019, after the 
catastrophic disasters caused by Cyclone Idai in the center of Mozambique. About 
4979 cases of cholera and six deaths were confirmed in emergency clinics created 
by the government of Mozambique aided by NGOs and other institutions [12], 
but until May the number of cumulative cases increased to 6766 and 8 deaths, 
according to the Health Cluster of Mozambique. Flooding and house destruction 
forced 68,974 displaced people living in accommodation places, making some 
places overcrowded, and increasing the risk of spreading cholera among the 
people there [1, 21].
The symptoms of cholera vary depending on the period of the infection. 
Between 18 h and 5 days, it is characterized by incubation period, followed by 
profuse watery diarrhea, rice-water stools, fishy odor to stools, vomiting, rapid 
heart rate, loss of skin elasticity, dry mucous membranes, and low blood pressure 
[24]. Most people are asymptomatic, but they remain carriers of the disease, excret-
ing the bacteria in their faces, usually for 2 weeks but occasionally for several years. 
Approximately 2.8 million cases and 91,000 related deaths are reported annually, 
and the spreading of this disease included insufficient access to clean water, reduc-
tion of immunity, and taking of antacids [25].
Without the access of clean water and sanitary facilities, thousands of families 
were at risk of cholera mainly children because they used to play in dirty water 
which were strewn bodies of humans and animals, and women, during the men-
struation period, sometimes needed to clean their bodies and only untreated water 
were available [8, 16]. In the beginning, the destruction of road and infrastructure 
corridor that connected Sofala to other parts, it was very difficult to help those 
people with water, food medical, and relief supplies, forcing the use of helicopters, 
rescue planes, boats, and ships [1, 3].
According to the Oxford Committee for Famine Relief (OXFAM), the 
Mozambican government worked quickly to set up cholera treatment centers in the 
city of Beira [22]. Supported by the WHO and funded by the GAVI (the Vaccine 
Alliance), more than 800,000 doses of oral cholera vaccines had been distributed 
in just 6 days, from 3 to 9 April 2019, since a vaccination campaign has launched. 
Fixed points were created to administrate vaccines to children and adults on schools 
and health center and on districts of Beira, Dondo, Nhamatanda, and Buzi [26]. It 
resulted in a decrease of the daily reporting number of cholera cases [1, 3, 14], with 
a cost of US$1.85 per dose [27]. They also provided supplies to purify their drink-
ing water and stop to spread the cholera [4], but the sanitization of drinking water 
can be achieved through boiling, and all food must be well cooked and consumed 
immediately [8]. After the humanitarian response plan had been created to respond 
the outbreaks across the globe, millions of doses of oral cholera vaccine have already 
been shipped in many countries [26].
5. Epidemiological accounts
According to the Health Cluster of Mozambique, there were a total of 6735 
cumulative cholera cases, as of 6 May 2019. Until 31 May 2019, the number 
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increased to 6766 cases, identified in emergency clinics, according to the National 
Situation Report [21].
The Figure 2 shows that the number of cases of the present outbreak is lower 
than 7073 cholera cases observed in 2015, even though Cyclone Idai caused a much 
higher destruction of infrastructure [3, 28]. The Ministry of Health of Mozambique 
declared a cholera outbreak on 27 March after the epidemiological conclusions 
made in areas affected by Idai, and more than 4000 cases were recorded in the city 
of Beira [1, 29]. Figure 2 shows how the number of confirmed cases of cholera 
increased from the day it was announced as an outbreak, up to 31 May.
As the capital of Sofala and because it is the most populous city in the province, 
Beira registered 4745 cases, followed by Dondo with 1094 cases, Nhamatanda with 
793 cases, and Buzi with 134 cases of cholera [20, 21, 29–31].
The Mozambican government, with the help of international entities, reacted 
to this happening with the supply of vaccines and water purification supplies, and, 
according to some reports, the daily reporting number of cholera cases reduced [1], 
but they do not show the numbers or percentages.
Cholera is just a part of the disasters; there were other concerns such as malaria, 
measles, respiratory infections, mental disorders, and the material damages. 
Restoration of the damages is still ongoing, and there are more people waiting for 
help; in some areas, people are already living in chronic poverty and now face huge 
challenges to survive.
6. Conclusions
Cyclone Idai hit the center of Mozambique in mid-March 2019 causing thou-
sands of deaths. The destruction of infrastructures contributed to the epidemiology 
of cholera, and the Ministry of Health declared a cholera outbreak on 27 March, 
after identifying more than 4000 cases, number that increased to 6766 until 31 
May; eight deaths in emergency clinics created to reduce the impact of diseases 
in that area. Flooding and overcrowding in accommodation places increased the 
risk of spreading cholera; however, considering the magnitude of the disasters 
caused by Idai, the outbreak of cholera was well managed with the efforts of the 
Mozambican government and partners, such as the WHO and CARE. Mozambique 
has already faced other outbreaks, which helped the country to create ways to 
confront the recent outbreak, due to Cyclone Idai.
Figure 2. 
Epidemiological curve of cholera outbreak attributed to Cyclone Idai, March–May 2019.
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Many infrastructures were destroyed, including roads, hospitals, schools, and 
houses, and only 17% of the money required had been provided. However, food, 
water, and medicine supplies arrived to the affected areas through planes, helicop-
ters, and boats. The outbreak was controlled certainly due to the setting up of treat-
ment centers and clinics, where more than 800,000 people were immunized with 
doses of oral cholera vaccines. They also provided supplies to purify the drinking 
water and campaigns to spread the information about treatment of water and food, 
resulting in a decrease of the daily reporting number of cholera cases. It is impor-
tant to know that even with all of this help, there are people who still need help.
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for Decisions for Multisource 





Following a national law introduced in 2017 in Thailand, the selection of win-
ning bidders for multisourced pharmaceuticals and medical supplies in public 
hospitals must reflect “price-performance” aligned with the principles of worthi-
ness, transparency, efficiency, effectiveness and accountability. We describe how a 
practical tool using Multiple Criteria Decision Analysis (MCDA) for evidence-based 
decision making in hospital bidding (tender) was developed through a multi-
stakeholder workshop format. The local leader of the initiative together with 2 
international advisors guided the 37 workshop participants through five interactive 
steps for local adaptation of the previously developed and validated global MCDA-
tool: (1) Criteria selection, (2) Scoring definition, (3) Weighting of price criterion, 
(4) Definition of cut-off point for price criterion, (5) Ranking and weighting of 
remaining criteria. All consensus judgments were imported to the decision tool 
which can later be used in the real-world situation in the hospitals to support the 
selection and document the underlying rationale. The final list of criteria differs 
from the previously suggested international template and now reflects the Thai 
decision priorities and current decision processes. In the book chapter, the resulting 
model will be presented and a pathway for implementation will be discussed.
Keywords: multiple-criteria decision analysis, MCDA, Thailand, multisource 
pharmaceuticals, hospital tender, hospital bidding, performance
1. Introduction
Pharmaceutical procurement in Thailand has a long history of deconcentration of 
procurement management and decisions to the Provincial Health Office (PHO) and 
all public hospitals. This includes the delegation of power to generate, retain, and 
use financial revenues according to regulations and subject to regular audits by the 
auditor general [1]. Thus, purchasing for hospital pharmaceuticals is strongly decen-
tralized. Before the deployment of the Public Procurement Act BE 2560 (AD 2017) 
in 2017, the single selection criterion in the tender or bidding, as called in Thailand, 
was the lowest price. Since the establishment of Public Procurement Act, the bidder 
selection for multisourced supplies, including pharmaceutical and medical products, 
Evaluation of Health Services
78
has been expanded beyond “price” to “price-performance” in order to align with 
the principles of the Act concerning worthiness, transparency, efficiency, effective-
ness, and accountability. While public hospitals are encouraged to use performance 
criteria to determine the suppliers for pharmaceutical products, there is still a lack 
of a standard definition of what these criteria encompass and how important each 
of them is in making the decision. This may lead to a high level of variation between 
the hospitals on the formulary composition and in the methods used to shape the 
specific bidding process. To increase the overall quality and transparency based on 
the Public Procurement Act BE 2560 (AD 2017), the government is now requiring a 
solid rational and transparent documentation of hospital purchasing decisions.
Multiple-criteria decision analysis (MCDA) is a method which has been sug-
gested as a tool for the evidence-based assessment of multisource pharmaceuticals 
in developing countries [2]. MCDA can help to consider multiple and sometimes 
conflicting criteria in the evaluation of the available alternatives [3].
By considering multiple criteria, individuals or groups can follow an explicit 
structure for arriving at a decision that best fulfills the criteria [4]. In 2016, a task 
force of the International Society for Pharmacoeconomics and Outcomes Research 
(www.ispor.org) set out to give guidance for the best practices of MCDA in healthcare 
decision-making [5, 6]. In this, the development and use of MCDA are described as 
an iterative process containing several elements, which may be adapted to the specific 
use by the key stakeholders involved in the decision. At the start, it is important to 
define the decision problem with the objective, the stakeholders, the expected alter-
natives, and the expected output. Based on this, criteria for evaluation can be deter-
mined which reflect the important attributes or drivers for the success in the decision. 
For each of the criteria, a scoring scale or graduation needs to be determined. If the 
criteria (or attributes) have a different importance in reaching the overall objective, 
the criteria will have to be weighted according to their importance [5, 6].
In the actual evaluation of the alternatives, the performance in each criterion is 
scored separately for the available alternatives and contributes with the predeter-
mined weight, according to its relative importance, to the composite score reflect-
ing the overall performance of the alternative.1 When comparing alternatives, the 
MCDA will result in a “score profile” for each alternative and a composite score, 
which is generated by the MCDA model. The result is not the decision but structured 
information to better inform the decision to be made. MCDA is being used widely 
to inform decision-making in healthcare, including benefit-risk assessment of 
medicine, formulary listing, or reimbursement decisions [5, 7]. Examples for using 
MCDA in decision-making for multisource medicines in developing countries are 
emerging in several countries such as China, Thailand, or Egypt [8, 9]. MCDA could 
be a solution for hospitals in Thailand to select those products which best meet the 
needs of the patients, providers, and the national policy makers for healthcare.
Thailand has a strong history of using multiple-criteria decision analysis 
(MCDA), considering the value of pharmaceuticals as an important component in 
pharmaceutical policy planning, price negotiation, development of clinical practice 
guidelines, and communication with health professionals [10, 11]. It has been rec-
ognized that MCDA enhances the legitimacy of policy decisions by increasing the 
transparency, systematic nature, and inclusiveness of the process [10]. Examples 
for using the MCDA method on a national level for rational, transparent, and fair 
priority setting in the context of single-source drugs have been described [12].
The objective of this initiative was to develop a simple tool for improving 
decision-making in the hospital bidding setting, based on the MCDA methodology, 
1A short explanation of MCDA in lay language (English) can be seen under https://www.youtube.com/
watch?v=7OoKJHvsUbo.
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through a multi-stakeholder workshop format to attain consensus. This tool should 
integrate a set of standard decision criteria, which (1) can be used by hospital 
purchasers to base bidding decisions on both performance and price, (2) would be 
applicable across diverse hospitals and institutions, but (3) would also allow for 
adaptation to local priorities.
2. Methods
On June 29, 2018, key stakeholders and experts in pharmaceutical bidding 
policies in Thailand came together on invitation by the Pharmaceutical Association 
of Thailand under Royal Patronage (PAT). The 37 active workshop participants rep-
resented multiple perspectives in Thailand (24 pharmaceutical purchasing (12 of 
these from leading hospitals), 7 academic pharmacy education leaders, 4 from the 
Ministry of Health, 1 from PAT, and 1 from an industry association) in addition to 
2 observers from the regulatory perspective. During the 1-day workshop, all active 
participants were involved in developing an MCDA tool which can be used in mak-
ing decisions in the hospital bidding setting.
Two international health policy advisors moderated the workshop following a 
validated MCDA calculation model and process for local adaptation [13]. Together 
with the local leader of the initiative, the international experts used a structured 
process as described in Figure 1 to prepare the workshop, align the participants’ 
expectations and knowledge at the workshop, and to guide the workshop partici-
pants through five steps for the local adaptation of the MCDA format. The interna-
tional advisors conducted the workshop in English language. However, to ensure 
that all participants could follow the discussions and freely express their experi-
ences and opinions at all times, independent of their knowledge of either Thai or 
English, the workshop was supported by a two-way simultaneous translation.
The workshop started by defining all non-price criteria which may be 
relevant in the Thai decision process. These were defined starting from the 
Figure 1. 
Description of the entire process for developing a value-based decision tool for multisource pharmaceutical 
bidding in Thai hospitals.
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basic decision criteria proposed by international health policy thought leaders 
[2] and an adapted set of these criteria which had gone through a preliminary 
adaptation to current Thai decision priorities before the workshop, by the local 
leadership team of the initiative (Step 1). This involved a detailed moderated 
discussion of each of the criteria and of the measures used for scoring each of 
the criteria (Step 2).
Subsequently, the participants determined the weight of the price criterion (Step 3) 
in the overall decision and the acceptable price range and cutoff point qualifying a 
product for positive ratings on the price criterion (Step 4). After this, the relative 
importance of each of the criteria in the overall decision was determined following the 
modified simple multi-attribute rating technique (SMART) method [9] for ranking 
and swing weighting of the criteria (Step 5). Steps 3–5 included anonymous vot-
ing by the participants using an audience response system (Ombea® with OMBEA 
ResponsePad™). The results of each voting were shown directly to the audience. In 
case of large variations or disagreements between the voters, the arguments of the 
participants in support of their votes were deliberated in open discussion followed by a 
second voting. For the voting on price and the cutoff point, the result was computed by 
assessing the median value. For the ranking of the criteria, the majority vote was used 
in repeated voting rounds to select the most important of the remaining criteria.
An important step after the workshop will be the testing and validation of the 
tool in a realistic setting (piloting) with monitoring of the results, the revision 
based on the learnings during the pilot, and, finally, the full implementation as 
summarized in the right part of Figure 1.
3. Results of the workshop
The discussion among the participants confirmed that currently there is no 
uniform evaluation method applied to bidding decision-making in hospitals 
and that there is a need for more consistency and better decision documentation 
on one side but also a need to adapt the weighting or criteria to local situations 
in cases where there are special environmental conditions. In addition, there 
was a general agreement that the decision should not solely be based on price, 
because major differences relating to quality and reliability or other factors with 
the healthcare impact are observed in real life between the products offered by 
different suppliers in Thailand. The advantages of using a consistent approach 
involving the MCDA methodology would be, on the one hand, the improved 
decision consistency and equity and, on the other hand, the high transparency 
and documentation of decisions versus all stakeholders with interest in the 
decision (e.g., manufacturers, government agencies, quality control, hospital 
administration, and providers).
3.1 Pre-workshop preparation
Based on experience with the local legal-structural setting, desk research, and a 
pre-workshop survey among the workshop participants, the leadership team (Thai 
academic pharmacy experts with international advisors) described 11 relevant 
criteria, including:
• Six product quality criteria, equivalence with the reference (original) product, 
stability and drug formulation, product quality determined by the Certificates 
of Analysis (CoA) of both the finished product and the active pharmaceutical 
ingredient (API), and the product specifications of both the finished product 
and the API
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• Three criteria relating to the manufacturer quality, the manufacturing stan-
dard of both the finished product and the API, as well as the reliability of drug 
supply, pharmacovigilance, and added value service related to the product.
3.2 Workshop
3.2.1 Step 1: selection of non-price criteria
At the beginning of the interactive part of the workshop, the participants discussed 
and selected the most important non-price criteria which should be considered for 
determining the value of multisource pharmaceuticals starting from the set of criteria 
resulting from the pre-workshop preparation. During this discussion, several altera-
tions were adopted so that it finally resulted in 10 non-price selection criteria, of which:
Criterion name Scoring (possible outcomes) Score
Equivalence with the 
reference (original) 
product
No data on pharmaceutical equivalence 0%
Pharmaceutical equivalence 10%
Bioequivalence proven in compliance with the Thai FDA 30%
Bioequivalence approved by the Thai FDA and with the European 
EMA or US FDA standard
70%
Bioequivalence approved by the Thai FDA and with the European 
EMA or US FDA approval
80%
Therapeutic efficacy or equivalence proven in a clinical trial 100%
Stability and drug 
formulation
No data on product expiry or stability EXCL
Have data (1) long-term study (full shelf life), but do not follow the 
ASEAN guidelines
10%
Have data (1) long-term study (full shelf life) and follow the ASEAN 
guidelines
50%
Have data (1) and (3) latest yearlong-term stability study or (4) 
in-use stability data for the drug which needed to be mixed before 
use (drug to be mixed before use must have “in-use stability data”) 
but do not follow the ASEAN guidelines or have only data (1) which 
follow the ASEAN guidelines
75%






Limited information on quality assurance EXCL
Country of origin GMP quality assurance 33%
WHO GMP certification 67%
EU or PIC/S GMP 100%
Quality: certificate of 
analysis (CoA) finished 
product
Not comply with registered finished product specification EXCL
Partially comply with registered finished product specification EXCL




Do not comply with registered specification EXCL
Follow the previous pharmacopeia version or in-house specification 
with topics not aligned with the general chapters
50%




List of criteria with consensus scoring (qualitative descriptive) (Part 1).
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Criterion name Scoring (possible outcomes) Score
Quality: manufacturing 
standard API
Limited information on quality assurance EXCL
Country of origin GMP quality assurance 33%
WHO GMP certification 67%
EU or PIC/S GMP 100%
Quality: product specification 
API
Not comply with registered specification EXCL
Follow the previous pharmacopeia version or in-house 
specification with topics not aligned with the general chapters
50%
Follow updated pharmacopeia or in-house specification with 
topics recommended by pharmacopeia
100%
Added value service on the 
hospital level
No program or service 0%
Low value (meets one criterion) 33%
Moderate value (meets two criteria) 66%
High value (meets three criteria) 100%
Macroeconomic benefit The manufacturer has no local investment in the country 0%
The manufacturer has minor local investment in the country 33%
The manufacturer has moderate local investment in the 
country
67%
The manufacturer has significant local investment in the 
country
100%
Reliability of drug supply Major and multiple problems in the last 2 years 0%
Minor and occasional problems in the last 2 years 20%
Single precedence of supply problems in the last 2 years 50%
No precedent of supply problems in the last 2 years 80%




List of criteria with consensus scoring (qualitative descriptive) (Part 2).
• Five relate specifically to the product (equivalence with the reference (original) 
product, stability, and drug formulation, the product quality determined by 
the CoA of the finished product, and the product specifications of both the 
finished product and the API).
• Three relate to the manufacturer (the manufacturing standard of both the 
finished product and the API as well as the reliability of drug supply).
• Two relate to additional value beyond the actual product (added value services 
at the hospital level and macroeconomic benefit in terms of local investments 
by the manufacturer).
Two other criteria have been considered but were not adopted to the final essen-
tial list of decision criteria: The Certificate of Analysis for the API was considered a 
prerequisite to enter the bidding and, therefore, would not be relevant for further 
differentiation between the products; pharmacovigilance was also not considered 
relevant for the multisource pharmaceuticals used in the hospital setting. In addi-
tion, it was warned that this criterion might introduce an unfair bias toward the 
originator products who are usually the only ones pursuing a pharmacovigilance 
database on the national or international level.
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3.2.2 Step 2: criteria scoring
For all selected criteria, the measurement scales were discussed in some cases; 
the previously suggested rating were adapted by the participants as considered 
more appropriate in the Thai hospital setting. The detailed descriptions of the 
criteria scoring are listed in Tables 1 and 2.
3.2.3 Step 3: weight of price criterion
Subsequently, the relative importance of the price criterion was determined 
by voting and was determined to be 40% of the overall decision, which is already 
established as a general ratio for chemical pharmaceutical products.
Figure 2. 
Graphic representation of the scoring for the procurement price difference in comparison to the lowest price 
product. The cutoff point determined in the workshop was an excess price of 100%. All prices higher than this 
cutoff point receive a score of 0%.




Price Quantitative 1 40
Equivalence with the reference 
(original) product
Qualitative 2 12.2
Product quality: certificate of analysis 
(CoA) finished product
Yes/no (no = exclusion) 3 8.7
Manufacturer quality: manufacturing 
standard finished product
Qualitative 4 8.7
Stability and drug formulation Qualitative 5 7.3
Product quality: product specification 
(finished product)
Qualitative 6 5.8
Quality: product specification API Qualitative 7 4.9
Quality: manufacturing standard API Qualitative 8 4.0
Added value service on the hospital level Qualitative 9 3.1
Reliability of drug supply Qualitative 10 2.8
Macroeconomic benefit Qualitative 11 2.5
Table 3. 
Results of the consensus workshop for the relative importance of the evaluation criteria and their weight in the 
final score for each option.
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Figure 3. 
Impact of each decision criterion in the evaluation on the final decision (top axis: impact percentage). 
Abbreviations: CoA = certificate of analysis, Std. = standard, API = active pharmaceutical ingredient.
3.2.4 Step 4: scoring of price criterion
To enable a quantitative scoring function for the price criterion, the participants 
had to determine the cutoff point for the price. This median cutoff point was voted 
to be an excess price of 100% based on the acceptance threshold defined by the 
current guideline of Comptroller General’s Department. As shown in Figure 2, this 
means that all products with prices which are 100% or higher than the lowest price 
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offered in the bidding would receive a score of zero for the pricing criterion in the 
evaluation.
3.2.5  Step 5: ranking and weighting of non-price criteria by “SMART and swing” 
method
Finally, the selected criteria were ranked and rated for their weight in the 
final decision round [7]. The results are summarized in Table 3 in the column 
“Final weights.” The impact of each criterion on the final decision is shown in 
Figure 3.
3.3 Workshop follow-up
Finally, all participants agreed that the resulting model seemed appropriate to 
be used for selecting bidding winners in Thai hospitals and that it should be tested 
in real-life pilot applications. Hence, after the MCDA model has in this workshop 
been adapted to the Thai hospital decision context by Thai stakeholders from a 
broad range of healthcare-related institutions, two additional steps are important 
to ensure applicability in the hospital setting: (1) piloting and validating in real-life 
decision processes and (2) refinement based on the experiences in the piloting in 
selected hospitals. Realizing such a pilot application will require involvement of all 
functions concerned in the specific hospital decision process and their agreement. 
This will be facilitated through support from the local leader of the initiative.
4. Discussion
In this report we have described a structured process to adapt the template of 
a validated international multiple-criteria scoring decision format to the specific 
setting of making performance-based decisions for public purchasing in Thai 
hospitals. The involvement of a broad stakeholder group in the design process is 
critical for the acceptance and subsequent implementation of the methodology. In 
this workshop, there were 37 participants who represented the user perspectives as 
well as the administrative or regulatory perspectives, the academic expertise and 
the perspectives of the pharmacist profession through PAT and of the industry by 
representation of the Pharmaceutical Research and Manufacturers Association 
(PReMA, http://www.prema.or.th).
Although using a standardized process for the workshop and a previously 
designed Excel-based model template [13], the participants were involved in 
each step of designing the specific Thai decision tool during a 1-day workshop. 
Continuing the participatory process by involving the important purchasing stake-
holders in the pilots and the evaluation will further foster full transparency and 
improvement through user feedback, and, finally, it should support endorsement of 
the process in the specific Thai hospital bidding decision context. The participants 
agreed to the approach and considered the resulting MCDA tool to be suitable to 
improve the transparency and consistency of decision-making for multisource 
pharmaceuticals in Thai hospitals.
The MCDA model is a living instrument which can be revised when the priori-
ties and needs in the healthcare system and policies change. Therefore, criteria 
can be included, excluded, or adapted at a later stage once a new consensus on the 
importance and the transparent measures for qualification is reached among the 
users of the instrument due to new developments and experiences. For example, 
it has been proposed by some participants that some flexibility might be advisable 
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for the weighting of the price criterion when evaluating a specific type of product 
such as lifesaving medicines or a stricter scoring of the quality criteria when it 
comes to narrow therapeutic window drugs. An adaptation of the price weight 
depending on such considerations is possible on the hospital level if required. 
Another point for reconsideration after testing the tool in the real-life situation 
resulted from the discussion of the criterion of the “Certificate of Analysis for the 
finished product”: in the final model, the scoring was determined as either com-
plying with the specifications (=100%) or not complying (exclusion). Thus, this 
criterion may be considered as another prerequisite to enter the bidding instead of 
a MCDA decision criterion.
The final list of criteria selected in this initial workshop for the resulting MCDA 
model shows some deviations from the criteria which were previously suggested by 
an international expert group [2] and which were selected in other countries which 
adapted the tool to their settings [13]. This reflects the active engagement and 
contribution of the participants who critically questioned and deliberated each of 
the proposed criteria in comparison to their current decision processes.
After successful piloting, evaluation, and refinement of the model based on 
the real-life experience, a roadmap for further dissemination and implementation 
should be developed.
The process presented here for the adaption of a multiple-criteria scoring format 
to the specific decision problem in Thailand follows the general process as suggested 
by the ISPOR task force [5, 6]. The core elements in this process were addressed 
with a group of Thai stakeholders in the hospital purchasing processes, who repre-
sented a range of hospitals.
While the selection of criteria, the ranking, and the weighting require adapta-
tion to the specific decision problem and policy framework, the process itself can 
be generalized and transferred to other countries or organizations. The foundation 
for the course of work steps in preparation of the workshop, conduct of the work-
shop, and follow-up has been formed through the experience from three countries, 
Indonesia, Kazakhstan, and Vietnam [13, 14]. In each of these countries, different 
types of purchasing or tender decision problems (national purchasing, public 
tender) had been addressed. In this book, another example is presented, where the 
process was followed to develop a decision analysis tool to help provincial policy 
makers with the comparison of alternative insurance policies in China [15]. For 
that, a new set of decision criteria had to be compiled, which reflected the needs to 
be addressed by a policy change from the stakeholder perspective. However, despite 
that the objective to select the optimal future insurance policy is very different 
from the objective which guided the Thai initiative, the same process was followed 
in China: preparation with desk research and discussions with local stakeholders, 
workshop with consensus on the purpose of the tool, selection of the criteria, 
prioritization and ranking of the criteria, and follow-up with testing and piloting. 
The most important element is the engagement with and of those stakeholders 
who are concerned by the decision. How each of the procedural elements is shaped 
in the specific local application will strongly depend on the local preferences and 
needs. If the participating stakeholders are already familiar with the principles of 
MCDA, such as in Thailand, a 1-day workshop format may suffice. In Indonesia 
and Kazakhstan, a 2-day format was preferred which allowed for more presentation 
of the technical and methodological information before entering the interactive 
workshop parts. In all cases, we saw that the discussion at each step throughout the 
workshop is essential for building consensus.
Another important consideration should be that the current values and daily 
routines are considered when selecting the criteria. For example, the original 
list of internationally validated criteria was modulated in Thailand to satisfy the 
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traditionally high use of specific quality measures. If the MCDA process shall be 
used for tender decisions, it will be important to train the users who may previ-
ously only have used the price or a very limited amount of information to select the 
winning bid. A standard template for dossier submission may facilitate the targeted 
supply of data and information for the manufacturers, a standard template for data 
as has been proposed by Brixner et al. in consequence of the experiences in the pre-
vious workshops [16]. Increasing experience with the implementation for further 
applications in CEHCs and ongoing evaluation and communication will help in the 
efficient implementation of new initiatives.
A limitation of the approach presented here for developing a MCDA tool to be 
used for hospital purchasing may be that the initial design is limited to the num-
ber of participants and the breadth of stakeholder groups involved in the design 
workshop. However, further involvement will be achieved throughout the pilot-
ing through communication of the experiences after each step of the process and 
through updating of the tool based on the practical experience.
5. Conclusions
The present paper describes how MCDA can be easily adapted to different 
countries and decision-making settings to improve the efficiency and transparency 
of the decision-making process, in the case of the undertaking of pharmaceutical 
bidding. The approach described here can be easily adapted to other countries and 
decision-making settings.
A short explanation of the principles of multiple-criteria decision analysis and 
the use in decisions on pharmaceuticals can be viewed at https://www.youtube.com/
watch?v=7OoKJHvsUbo.
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The Burden of Informal Caregivers 
of Alzheimer’s Patients: An 
Estimation to Portugal
Aida Isabel Tavares and Carolina Freitas
Abstract
The demographic phenomenon of ageing is speeding up in Europe. People live 
longer and so the prevalence of dementia increases, including Alzheimer’s disease. 
This is a progressive disease in which people slowly lose their cognitive and physical 
capacities until death takes over. Alzheimer’s disease not only imposes a very high 
burden in the affected person but also inflicts a high and overwhelming burden of the 
caregivers. The carers’ burden includes health deterioration, labour damaging and 
loses and financial and social costs, while the care provided is not well valued. The 
aim of this chapter is to review the main trends and concepts related to ageing, care-
givers and Alzheimer’s disease. It also presents the economic burden associated with 
the disease and the monetary value of the care provided by caregivers in Portugal.
Keywords: informal care, Alzheimer’s disease, burden of disease, Portugal
1. Introduction
Alzheimer’s disease is the most common form of dementia, and it accounts 
for about 60–70% of the 50 million people suffering from dementia worldwide 
[1]. This means that between 30 and 35 million of people suffer from Alzheimer’s 
disease across the world. However, the numbers of those with this disease may be 
underestimated as only about 40–50% of the cases of dementia are identified in 
developed countries [2].
Dementia and, in particular, Alzheimer’s disease are a major reason for the dis-
ability and dependency across older people. The individual impact burden due to this 
disease is broad. It includes physical, psychological, social and economic aftermaths. 
But also the burden is shared with carers, families and society in general [1]. About 
50% of carers say that their own health was affected by the responsibility of caring 
their Alzheimer’s patients despite their positive sentiments about their role [3]. The 
economic repercussions of Alzheimer’s disease are diverse, and they include the direct 
medical costs, the social care costs and the costs of informal care. The magnitude of 
these economic repercussions cannot be ignored neither by society nor by politicians.
The aim of this chapter is of twofold. Firstly, we review the phenomenon of 
ageing and describe the increasing prevalence of Alzheimer’s disease; additionally, 
we highlight the relevance of informal care and the burden supported by informal 
caregivers. Secondly, this chapter aims to describe the social and financial burden of 
informal caregivers of Alzheimer’s patients in Portugal and to estimate a monetary 
value for the care they provide and have to bear.
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The chapter proceeds with a section describing the ageing phenomenon and 
Alzheimer’s disease, as well as the increasing prevalence of this disease. Next, it 
reviews the type of care available to deal with Alzheimer’s patients, and a particular 
emphasis is placed on informal care. In the following section, the socio-economic 
burden of informal caregivers is outlined. The chapter continues with a section 
presenting the estimation of the financial burden of carers of Alzheimer’s patients 
in Portugal followed by a conclusion section.
2. Ageing and the Alzheimer’s disease
The current major demographic phenomenon in Europe is ageing. The share 
of older people in the population is increasing, and the age distribution picture is 
changing to an oval shape, and it is tending to look like a block. The ageing trend 
may be explained by (i) the increased longevity of people, (ii) the declined fertility 
and (iii) the ageing of “baby boom” generations.
In Europe, as the cohort of baby boomers gets older, the wider stripes of the 
pyramid move up in direction of the top of the pyramid. Younger generations 
and their low fertility are reflected by their narrow stripes at the base of the age 
pyramid. As the time goes by, the top highest age group of the pyramid enlarges 
as an increasing large share of very old people who are living longer lives 
(Figure 1) [4].
So life expectancy has been increasing and people are living longer. These longer 
lives may be lived in a healthy status, but most likely the additional years of life are 
lived in unhealthy conditions, in particular, the last years of life. Among the health 
conditions, the most prevalent in older ages is dementia, which includes Alzheimer’s 
disease. This health condition is not a consequence of the ageing natural process, 
but it has a high prevalence among the older group of people [5]. It generates high 
economic and social costs, and for this reason it may be considered as one of the 
great challenges of society nowadays [5].
Figure 1. 
Population age pyramid in Europe.
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Dementia (and Alzheimer’s disease) is a syndrome, chronic or progressive, 
characterised by an abnormal and fast decline in the ability of people to reason 
and think (the decline of the cognitive function). Although consciousness is not 
affected, the remaining capacities are strongly diminished such as memory, think-
ing, orientation, comprehension, calculation, learning, language and judgement. 
Additionally, there is a decline in the emotional control and social behaviour [1].
Life expectancy for an Alzheimer’s patient, after his diagnosis, is about 10 years. 
There are three stages of progressive gravity of the disease: early (2–4 years), mild 
(2–10 years) and late (1–3 years or more) stages. In the early stage, illness goes 
unnoticed, and its signs include forgetfulness, losing oneself in familiar surround-
ings and losing track of time. As the illness progresses, at the mild stage, the signs 
become clear, and patients begin to forget recent events and people’s names, forget 
where they are, have difficulty communicating with others, need help with personal 
care and start to show behavioural changes as wandering and repeat questioning. 
When the last stage is reached, Alzheimer’s patients are inactive and dependent. 
Their memories are seriously damaged and physical signs are obvious.
The clinical dementia rating (CDR) is the clinical instrument that measures the 
severity of dementia, including Alzheimer’s disease. This instrument evaluates six 
domains of cognitive and functional performance of patients, including memory, 
orientation, judgement and community affairs. This instrument scores the patients 
impairment in five levels so that medical intervention is more adequate and effective.
CDR is not a clinical diagnosis; it rather is a measurement scale that helps the 
diagnosis of Alzheimer’s disease. In fact, there is no single test that provides a 
consistent diagnosis of Alzheimer’s disease. The diagnosis is a process of careful 
evaluation done by a multidisciplinary team which may include neurologists, geri-
atricians, nurses, psychologists and psychiatrists [6].
In Western Europe, in 2016, it has been estimated that 4,499,078 disability-
adjusted life years (DALY) were attributed to Alzheimer’s dementia disease 
[7]. Mortality associated to Alzheimer’s disease has been increasing in Europe 
(Figure 2). Women die more than men, but the rate of increase has been identical 
for both genders. This trend is expected under the current conditions of longer lives 
and advance medical knowledge.
Currently, there are no medicines that prevent Alzheimer’s disease or cure it, and 
so the numbers of patients and deaths will continue to grow, as well as the burden on 
the people suffering the disease, on the caregivers and on the health system as a whole.
3. Informal caregiver and the socio-economic burden
Caring of Alzheimer’s patients may take place in two frameworks, which may be 
supplemental or complementary: the formal care and the informal care.
Figure 2. 
Standardised death rate due to Alzheimer’s disease. Source: Based on Eurostat [hlth_cd_asdr2] [8].
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The formal care is supplied by the public or private sector and by its health-care 
professionals, who provide a service and are paid for that service. Across Europe, 
the number of formal carers is low. In some countries, such as Portugal, the number 
of formal carers is extremely low, less than an average of 2 long-term care (LTC) 
professionals per 100 older persons aged above 65 (Figure 3). While in some 
countries the number of LTC workers per old person has increased between 2011 
and 2016 (as in France and Croatia), in other countries there has been a decrease (as 
in the Netherlands, Estonia and the UK) (Figure 3).
Informal care is offered by someone who is close to the older patient, either fam-
ily, friends or neighbours. Informal carers provide help in a voluntary and non-paid 
manner. Usually caregivers provide assistance to patients in their own home, and 
this assistance is mainly directed for patients’ daily tasks [9].
Despite international data on informal carers is hard to compare and it is based 
in several sources of information, the OECD has gathered the information for 
several countries concerning the share of informal carers among the population 
aged more than 50 (Figure 4) [10].
In spite of being difficult to find numbers for informal carers along the time and 
across countries, it is expected that this number will not be sufficient to attend to 
the increased number of dependent older people [11].
The total cost of dementia in EU27 in 2008 was estimated in round number of 
$160 billion, and 56% of these are costs of informal care. While in Northern Europe 
the larger proportion goes for formal care, in Southern Europe the larger share is on 
the informal care [12].
The importance of informal care has become a more prominent issue recently, 
as the share of elderly in the population began to increase and as the LTC system 
funding began to be a social concern. Not only informal care is a cost-effective 
alternative, but also it is a well-being alternative for patients who may remain at 
their homes. So in several countries across Europe, different public supports have 
been offered to informal care as a form of incentive and as a support to families and 
friends of patients. That being so the distinction between formal and informal and 
paid and unpaid care is becoming unclear in European countries [13].
Informal care is provided at home, and it basically aims to help Alzheimer’s 
patients in activities of daily living (ADLs) and instrumental activities of daily 
living (IADLs) but also to give emotional support. ADLs are activities that include 
Figure 3. 
The number of LTC workers per 100 individuals aged +65, 2011 and 2016 (or nearest year). Note: LTC,  
long-term care. Source: OECD [9].
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basic self-care tasks such as walking, toileting, bathing, feeding and dressing. IADLs 
are self-care activities, which require some complex thinking, skills and organisa-
tion. These include managing finance, transportation, shopping, meal preparation, 
communication and managing medications.
Helping with these activities systematically along time is uncomfortable, 
unpleasant and overwhelming. Informal caregiving is emotionally rewarding, 
bringing up self-esteem and sense of worthiness and life mission. But it is a very 
demanding role, and informal carers very often suffer burnout and health problems 
[14]. On top of this, several carers have difficulties combining the care with their 
labour responsibilities, and some quit their jobs to be able to respond the patient 
needs. In fact, this decision may be harmful in their future as it compromises future 
employability and leads to permanent drop-out from the labour market [15].
Several studies have been devoted to estimate the cost of taking care of 
Alzheimer’s patients. In general, these costs depend on the number of hours of care, 
the severity degree of the disease, the use of formal care and the weather the carer is 
cohabiting with the patient [16].
The most used methods to estimate the monetary value of informal care to 
Alzheimer’s patients are those based on “stated preferences” and those based on 
revealed preferences, which include the “proxy-good method” (also called market 
cost method) and the “opportunity cost method” [17].
“Stated preferences” is a method to provide a monetary value to something that 
has no market value. It is based on questions collected by a survey. The answers are 
given in the form of monetary amounts, choices, ratings or other scales which allow 
the monetary value.
The “proxy-good method” values time spent on informal care at the market prices 
of a close market substitute. So an almost perfect substitute in the market needs to be 
found and used as a reference. The “opportunity cost method” values the informal 
caregiver’s benefit forgone due to spending time on providing informal care. Usually 
this is done using the individual’s wage rate. Both these methods do not cover all 
costs and effects of informal care, and so they are usually used as complements [17]. 
However, in our work due to the data availability, only “proxy-good method” is used.
Figure 4. 
Informal carers as a % of total population, EQLS 2016. Source: EQLS 2016, figure adapted from EQLS 
overview report [10].
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Concerning the care provided, data is collected using the instrument called 
Resource Utilization in Dementia (RUD), which provides information relative to the 
formal and informal care given to the patient according to his level of dementia [18].
4. Estimation of the burden of carers in Portugal
It has been estimated that the number of people with dementia in Portugal, in 
2012, was 182,526 in a population of less than 10 million people. This number rep-
resents about 1.7% of Portuguese population, and it is higher than the EU averages 
of 1.55% [19] (Alzheimer Europe 2019). Considering that 60–70% of those patients 
with dementia suffer from Alzheimer’s disease, it means that currently there are 
more than 110,000–128,000 Alzheimer’s patients in Portugal. It is estimated that in 
the next 20 years, the number of Alzheimer’s patients in this country will be around 
322,000 [9].
The current health expenditure (CHE) in Portugal directed for long-term care 
(LTC) has two functions, both social and health. Despite the inexistence of the EU 
average reference and comparing with Sweden which has some well-functioning 
long-term care system, Portugal presents a low share of expenditure (CHE) in 
long-term care expenditure for health but a reasonable level for long-term care 
expenditure for social support (Figure 5).
Public aid to informal caregivers in Portugal is in its infant stages, and the formal 
care is insufficient for the current demand. This national institutional framework 
pushes nearly all the care of Alzheimer’s patients to their families, who have stood 
for the overwhelming task of taking care of them, even if they do it with affection 
and love or even if they have no conditions to do so.
4.1 Method for collecting data
To collect data for Portugal, a questionnaire based on RUD, which includes 
questions about the informal caregiver concerning their socio-demographic char-
acteristics, health status, received external support, professional status, activities 
performed and time management, was used [20].
This questionnaire was applied over 5 months, in 2018, in the Neurology 
Services of the Hospital Centre of the University of Coimbra, Portugal, to informal 
caregivers of Alzheimer’s patients. This study has been approved by the ethical com-
mission of the hospital centre, and participants have signed an informed consent 
form. Confidentiality and anonymity are guaranteed to participants in this study.
Figure 5. 
Share of LTC expenditure in total current health expenditure. Note: LTC, long-term care expenditure.  
Source: Based on Eurostat [hlth_sha11_hc] [8].
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The study includes 86 Alzheimer’s patients and 97 informal caregivers. The differ-
ence in these numbers is due to the fact that some patients have more than one carer.
4.2 Descriptive results
Alzheimer’s patients were on average 75 years old, and about 60% were women; 
around 28% were in the very early stage of the disease, 28% were in the mild stage, 
20% were in the moderate stage and, finally, about 24% were in the severe stage.
Informal caregivers were on average 60 years old, and the majority of them 
(about 67%) were women, 53.6% of carers live in the same home as the patient, 
50.5% are spouses, ad more than 60% of carers reported suffering some health 
problem; and nearly 50% reported being professionally inactive, the remaining 
share of carers reported being absent from work for about 4 days a year to comply 
with the patient needs, and 70% of them report penalties in terms of salary and day 
off reduction and hour replacement from these work absences.
Lastly, it must be highlighted that 90% of the carers have no public financial 
support, and so all expenses are supported privately, by the patient, by the carer or 
by the family budget.
4.3 Estimated monetary costs
The results concerning the costs and monetary values relatively to the informal 
caregivers are expressive and informative for policymakers. From the point of 
view of the cost with health care supported by caregivers, data shows that the total 
amount spent annually is almost 590€ or almost 50€ a month. These costs are 
reported by caregivers (Table 1).
From the different activities performed by caregivers for their patients, data 
obtained from the questionnaire unveil that the activities that absorb the highest 
share of daily hours are the activities of daily living (ADL), such as toilet visits, eating, 
dressing, grooming, walking and bathing, and the instrumental activities of daily 
living (IADL), such as shopping, food preparation, housekeeping, laundry, transpor-
tation, taking medication and managing financial matters and supervision (Figure 6).
Finally, according to hours of care provided for the Alzheimer’s patient, the 
total average annual monetary value of those hours may be estimated. Taking into 
account the average number of daily hours of care and the monetary value of each 
hour (the value is estimated using the proxy-good method), the total average annual 
value of care sums up to 14,152.32 euros (Table 2). The values may vary according to 
the level of severity of the disease. At the most severe level of severity, these values 
decrease because there is an increasing share of burden with formal care.





Total annual average costs 586.44
Total monthly average costs 48.87
Source: Freitas [20].
Table 1. 
Annual average costs supported by informal carers.
Evaluation of Health Services
98
Summing up, the burden taken by an Alzheimer’s patient caregiver includes the 
costs related to labour absence, to the lack of social activities and to health deterio-
ration which may be reflected in health-care costs or untreated health conditions. 
These health-care costs were valued by 586.44€ average a year, even though caregiv-
ers seldom find time to look after themselves.
On the other hand, the caregivers provide care which was estimated to value 
over an average of 14,100€ per year, mainly resulting from daily activities and 
supervision activities. However, these values may be underestimated. On the one 
hand, caregivers tend to under-report the time spent providing care; on the other 
hand, the proxy-good method does not account for all cost, and it undervalues some 
activities, because they are associated with low labour market qualifications.
5. Conclusion
Undoubtedly one of the great challenges of society nowadays is to deal and 
to manage the increasing trend of Alzheimer’s patients in families as well as its 
associated increasing burden in the suffering individuals, in their caregivers and in 
society in general.
The care provided to Alzheimer’s patients may be formal or informal. In the 
latter case, it is provided by family, neighbours and friends in the patient home. The 
burden imposed on carers is heavy. It includes health deterioration, labour negative 
impacts, inexistent social life and a cost of the time spent helping the patient with 
their daily activities and supervising their actions.
In this chapter, the burden and value of caregivers of Alzheimer’s patients in 
Portugal were estimated and presented. The values may be underestimated, but 
they serve as a floor cost reference for policymakers. Several measures may be 
Average Numbers Total Early 
stage




No. of daily hours 10.8 9.7 10.5 11.8 11.7
Daily cost € 45.36 40.74 44.10 49.56 49.14
Days of week 6 5.7 6 6.3 6.3
Week cost (7 days) € 272.16 232.22 264.60 312.23 309.58
Annual cost (52 weeks) € 14,152.32 12,075.34 13,759.20 16,235,86 16,098.26
Source: Freitas [20].
Table 2. 
Monetary value for care given by the informal carer.
Figure 6. 
Distribution of daily hours across activities. Source: Freitas [20].
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undertaken in order to alleviate the burden supported by these carers. For instance, 
substitute carers, supplied by the health or social system, could coordinate tasks 
and daily help so that the caregiver himself could have more time to do other 
things such as go medical consultations, sleep and perform other social activities. 
Another measure that would be welcome is to provide a complementary subsidy 
for the patient expenditures in medical treatment and formal care. In this way, the 
caregiver budget would be protected, and it could be used on the carer’s own needs. 
Informal care is an increasing substitute and complement of formal care, and it 
should be valued from a societal perspective. Caregivers must be looked after and 
protected for their valuable contribution to society.
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Socioeconomic Burden of Disease
Using National Health Insurance
(NHI) Data
Hyeon-Jin Choi and Eun-Whan Lee
Abstract
The cost-of-illness (COI) studies convert the burdens associated with certain
illnesses into economic and monetary values so as to measure the socioeconomic
costs that are inevitably incurred by a given society in association with certain
illnesses. The estimated costs provided by COI studies provide an important basis
for estimating the amounts of public health resources spent and productivity losses
incurred and thereby make it possible to quantify the socioeconomic burdens that
illnesses impose on society in general. In this chapter, we review the diverse meth-
odologies and techniques for estimating the socioeconomic burden of disease,
which is widely used in the established literature all over the world, and compare
the pros and cons of each. This chapter introduces the existing COI studies in terms
of their research designs, data selection and value assessment processes, applied
perspectives, and chosen components of costs. Furthermore, this chapter introduces
a real-world example of estimating the national economic burden of disease by
using the National Health Insurance (NHI) data. We hope that this chapter will
help readers better understand and use the COI study.
Keywords: socioeconomic burden of disease, economic burden of disease,
cost of illness, cost of disease, financial burden of disease, disease cost
1. Introduction
The cost-of-illness (COI) studies convert the burdens associated with certain
illnesses into economic and monetary values so as to measure the socioeconomic
costs that are inevitably incurred by a given society in association with certain
illnesses. The estimated costs provided by COI studies provide an important basis
for estimating the amounts of public health resources spent and productivity losses
incurred and thereby make it possible to quantify the socioeconomic burdens that
illnesses impose on society in general. In other words, COI studies provide impor-
tant information for determining the socioeconomic costs of illnesses, which, in
turn, makes it possible to better prioritize public health policy tasks and issues. In
particular, the findings of such studies tend to be straightforward and intuitive and
aid policymakers in making related decisions.
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In this chapter, we review the diverse methodologies and techniques for esti-
mating the socioeconomic burden of disease, which is widely used in the established
literature all over the world, and compare the pros and cons of each. Furthermore,
this chapter introduces a real-world example of estimating the national economic
burden of disease by using the National Health Insurance (NHI) data.
2. Review of methods for estimating the costs of illness
This section introduces the existing COI studies in terms of their research
designs, data selection and value assessment processes, applied perspectives, and
chosen components of costs.
2.1 Study designs
COI studies can be roughly divided into two groups, depending on the
approaches they adopted to estimate the socioeconomic costs of illnesses. These
two approaches are the incidence-based approach and prevalence-based
approach [1–3].
2.1.1 Incidence-based approach
The incidence-based approach involves estimating the socioeconomic cost of a
given illness throughout the entire lifespan of the illness, from its initial stage to the
patientʼs complete recovery or death. This involves estimating not only the eco-
nomic burden currently imposed by the illness but also the cost of future health-
related losses, including those caused by sequela. This approach allows the
researcher to identify economic losses over time, from the present into the future,
but makes it impossible to take into account patients who have already suffered
from the same disease. In other words, the incidence-based approach may not be
well suited to estimating the economic burdens of certain types of illnesses (i.e.,
those that currently have low incidence rates but high prevalence rates) at certain
moments in time.
2.1.2 Prevalence-based approach
Contrary to the incidence-based approach, the prevalence-based approach con-
siders economic burdens accruing from not only existing patients suffering from a
given illness for a fixed period of time but also from future and potential patients.
This approach is well suited to estimating the economic costs of an illness at certain
points in time but may not allow the researcher to estimate the cost accrued
throughout the lifespan of the illness, from its initial stage to the patientʼs complete
recovery (or death). Furthermore, this approach may not be so amenable to esti-
mating the costs of frequent yet short-lived illnesses that do not last long enough for
the researcher to find and identify suitable patients within a given period of time.
The prevalence-based approach is by far the more popular method used in
previous studies. This is because it is important to take into account both new and
existing patients suffering from the given illnesses in order to estimate the socio-
economic costs of those illnesses during certain periods.
The characteristics and pros and cons of these two approaches are summarized
below (Table 1).
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2.2 Data selection
COI studies can also be divided into top-down and bottom-up studies,
depending on how the data used were obtained [4, 5].
2.2.1 Top-down studies
Top-down COI studies make use of data concerning the entire given population,
including the entire range of diseases affecting that population on the national level,
and then separate the diseases one by one to estimate their individual costs. In
Korea, the most favored source of data for such studies is the billing information
kept by the NHIS. Billing data provide a convenient glimpse into the total socioeco-
nomic costs of illnesses in the given society. However, the vast scope of these data
can easily lead researchers to include in their estimates expenses and costs that are
not directly related to the given illness (e.g., costs of prescriptions or medical tests
due to sub-diseases).
2.2.2 Bottom-up studies
Bottom-up COI studies review all relevant individual illnesses and then estimate
the total socioeconomic cost of these illnesses for the given nation. These studies use
the medical records of individual patients to estimate the costs for individual
patients and then expand those estimates to arrive at the total cost for the entire
group of patients affected. While this method affords relatively greater accuracy in
estimation than the top-down method, it is, realistically, quite difficult to estimate
the national socioeconomic cost due to the sheer volume and complexity of the data
on individual patients. There may also be regional disparities in the availability and
use of healthcare services, meaning that the resulting data may fail to represent the
entire given society.
Incidence-based approach Prevalence-based approach
Description • Estimates the economic cost of an
illness throughout its lifespan,
ranging from the initial stage to the
patientʼs complete recovery (or
death)
• Estimates the economic cost of an
illness during a certain period of time
by taking into account the costs
generated by both new and existing
patients
Pros • Allows the researcher to consider not
only the current cost but also the
future cost of an illness and the
sequela it causes and thereby
estimate the economic losses
incurred both in the present and the
future
• Better suited to estimating the
current cost of an illness
• Allows the researcher to consider
both new and existing patients at
given point(s) in time
Cons • Makes it difficult for the researcher
to consider existing patients that
have already been afflicted with the
given illness
• Not applicable to illnesses that, at
present, have high prevalence and
low incidence rates
• Makes it difficult for the researcher
to estimate the total economic cost of
an illness throughout its entire
lifespan
• The researcher may not find patients
suffering from the given illness if the
illness lasts for relatively short spans
of time, despite its high incidence
rate
Table 1.
Comparison of approaches to estimating the socioeconomic costs of illnesses.
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2.3 Value assessment
In general, there are two ways to evaluate and estimate the indirect socioeco-
nomic costs of illnesses (namely, losses of labor and productivity). These are the
human capital approach and the willingness-to-pay (WTP) approach [6, 7].
2.3.1 Human capital approach
The human capital approach is the most commonly used method for estimating
the value of human life and the costs of illnesses. Viewing humans as productive
actors, this approach estimates the current value of a human life as the discounted
future expected income.
In estimating the socioeconomic costs of illnesses, this approach posits patients
as productive actors and applies specific discount rates to the income they would
have earned through their labor in order to estimate their losses of working hours
and resulting losses in productivity. This method equates the costs of death and
illnesses to the losses of future total income that patients could have earned had they
remained healthy. This approachʼs focus on the losses of labor productivity caused
by individualsʼ illnesses reveals the opportunity costs of illnesses and death.
This approach is favored because the data it requires for estimating costs are
relatively readily available and the outcomes of the analysis are relatively less
influenced by the researcherʼs bias or subjective interpretation. Moreover, this
approach translates the direct costs (e.g., costs of healthcare service) and indirect
costs (e.g., losses of productivity) incurred by illnesses into losses of future income,
estimated on the basis of the patientsʼ current income level. However, this approach
may be discriminatory, in effect, against certain underproductive groups, such as
students, housewives, and seniors. Some also criticize the approach for its implied
ethic, i.e., that the value of human life can be measured on the basis of a personʼs
ability to earn income. Finally, the approach also runs the risk of underestimating
the intangible costs of illnesses, such as declines in quality of life and psychological
suffering.
The human capital approach is the approach most commonly taken by the
majority of studies. Compared to the WTP approach, the human capital approach is
less time-consuming, more cost-effective, and better suited to ensuring the objec-
tivity of analysis results, as it excludes the researcherʼs bias. Most importantly, it
clearly quantifies losses of productivity due to illnesses based on patientsʼ income
levels.
2.3.2 Willingness-to-pay approach
Also known as the contingent valuation method, the WTP approach estimates
the economic value of something that is not easily converted into a monetary sum
by surveying how much people would be willing to pay for it. COI studies adopting
this approach ask survey participants how much they would be willing to pay to
maintain or improve their health. This approach acknowledges the very common-
sensical assumption that peopleʼs preferences for things that are not easily mone-
tized can be used to estimate the economic values of those things. However, as this
approach requires people to estimate the economic values of things that they are not
used to monetizing, the answers given by survey participants may not be a reliable
measure of the true value of those things. The questions used to survey peopleʼs
willingness to pay can be either open-ended or close-ended. Open-ended questions
ask participants to state the maximum amounts of money they would be willing to
pay, while close-ended questions provide a few options from which participants
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may choose. Close-ended questions can be further divided into questions that apply
bidding games and that use the dichotomous choice method. Questions using bid-
ding games identify the maximum amounts people would be willing to pay by
presenting them with a series of specific amounts of money and asking them
whether they would be willing to pay such amounts. Questions that use the dichot-
omous choice method, on the other hand, present participants with two options of
monetary sums at each time and proceed to the next pair of options depending on
which of the preceding options the participants chose. The dichotomous choice
method imposes relatively less cognitive burden on participants in deciding the
economic values of certain things and allows them to arrive at a decision even in the
absence of in-depth knowledge of the market situation. However, the answers that
participants choose through this method may be merely the amounts of money they
view as acceptable to pay, and not the maximum amounts of money they would be
willing to pay. In applying this method, it is also difficult for the researcher to
decide the proper intervals between the figures to be presented, meaning that it
may take quite a long time for the researcher to identify the final amount of money
that participants would actually be willing to pay.
The table below provides a summary of the differences between the human
capital approach and the WTP approach (Table 2).
2.4 Perspectives of analysis
The conclusions of analyses on the costs of illnesses may be dramatically differ-
ent depending on which perspective the researchers chose to adopt. Since first
attempted and defined, COI studies have been a popular topic of research and
Human capital approach WTP approach
Description • Assesses the value of oneʼs current
life in terms of oneʼs discounted
future expected income
• Regards humans as productive
actors and estimates the costs of
illnesses as losses of working hours
or productivity
• Surveys people on how much they
would be willing to pay for certain
things
• Estimates the costs of illnesses based
on how much individuals would be
willing to pay to maintain or improve
their health
Pros • Ease of accessing required data.
• Ease of quantifying losses of
productivity caused by illnesses
based on patientsʼ income levels
• Results less influenced by personal
bias
• Able to measure the values of even
things not easily monetized
• Uses peopleʼs tacit preferences for
certain things to estimate the
economic values of those things
• Capable of counting even intangible
costs, such as quality of life and
psychological suffering
Cons • Discriminatory against
underproductive groups, such as
students, housewives, seniors, etc.
• Minimizes human life by measuring
it solely on the basis of individualsʼ
ability to earn income
• Incapable of measuring intangible
costs of illnesses, e.g., declines in
quality of life and psychological
suffering
• Decides the values of things solely on
the basis of peopleʼs subjective
preferences
• Participants may have difficulty
monetizing things that they usually
do not monetize, meaning that their
answers may be less than reliable as a
result
Table 2.
Comparison of approaches to estimating the costs of illnesses.
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debate among many researchers worldwide. Analyses in the established literature
today are largely guided by three perspectives: namely, the payer perspective, the
patient perspective, and the societal perspective [8–11].
2.4.1 Payer perspective
The payer perspective focuses on the costs of illnesses that are paid by insurers
and not patients. In South Korea, these costs are the costs covered by the NHI or the
healthcare costs confirmed by the Health Insurance Review and Assessment Service
(HIRA). These covered costs can be either narrowly construed as only the amounts
paid by the insurer or more broadly construed as including the amounts of
copayments made by patients as well. Taking the broad meaning would thus require
the estimation of the healthcare costs confirmed by the HIRA, which encompass
both the costs paid by the insurer and the copayments made by patients.
2.4.2 Patient perspective
The patient perspective requires the researcher to analyze and estimate the costs
paid by patients due to given illnesses. These costs include the direct healthcare and
non-healthcare costs and indirect costs. The direct healthcare costs include the
copayments made by patients, the non-covered costs, and the costs of informal
medical services, while the direct non-healthcare costs include the expenses
patients have to pay in order to receive medical services, such as transportation
expenses. Finally, the indirect costs include the costs incurred by patients in terms
of time and the costs of caregiving.
2.4.3 Societal perspective
The societal perspective leads to the estimation of the costs estimated from both
the payer and patient perspectives and the losses of societal productivity caused by
the given diseases. In other words, the costs estimated based on this perspective
include the costs of lost labor and productivity due to patients taking leaves of
absence or dying prematurely. These costs may also encompass the costs of declines
in quality of life and the psychological suffering of patients.
The table below summarizes the differences among these perspectives
(Table 3).
2.5 Components of costs
Existing studies that embrace the societal perspective generally posit several
specific components of the costs subject to analysis, including direct costs, indirect
costs, and intangible costs [8, 11–13].
2.5.1 Direct costs
Direct costs refer to the amounts of money spent directly on treating or manag-
ing a given illness or more specifically, the amounts of money spent at medical
institutions for the treatment and management of such illness. These costs can be
further broken down into direct healthcare costs and direct non-healthcare costs.
The direct healthcare costs include the costs of outpatient and/or hospitalization
services and purchasing medications (including prescribed medications) to treat the
given illness. Furthermore, it includes the costs incurred by outpatients and
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hospitalized patients alike due to disease, encompassing covered costs paid by
insurer, copayments paid by patients, non-covered costs, and prescription costs.
The direct non-healthcare costs refer to the expenses paid by patients to visit and
use the services of medical institutions, such as the costs of transportation and
caregiving.
2.5.2 Indirect costs
Indirect costs refer to the losses of labor and productivity that are incurred in
addition to the tangible (financial) costs of an illness. Examples include the amounts
of time taken off (paid) work to go to medical institutions and the loss of future
expected income, not only of patients but also of their family members or other
loved ones who are compelled to care for them. The latter example may also be
expressed as the opportunity costs of being ill, including the losses of working hours
and leisure time.
The indirect costs, or losses of productivity, are estimated by defining the num-
ber of hospitalization days as the number of working days lost and the amounts of
time spent for outpatient visits, as losses of working time. The losses of future
income are due to the premature deaths of patients.
2.5.3 Intangible costs
The intangible costs represent the decline in the quality of life and psychological
suffering of patients and loved ones. However, it is notoriously difficult to define
and quantify these costs with precision (Drummond et al., 2005). Due to the
scarcity of related data and the difficulty of quantification, researchers often forgo
estimating these costs (Table 4).



































Costs estimated based on different perspectives.
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3. Example of COI research using NHI data
In this section, we present example of estimating cost-of-illness research using
NHI data. This example titled “Socioeconomic Cost of Allergies” estimates the
socioeconomic costs associated with allergic diseases using NHI data in South Korea
[14]. In South Korea, all citizens are compulsory subscribers to the NHI scheme,
which is a type of social insurance, and all medical institutions or health profes-
sionals are required to submit claim data to the NHI to charge the bill for the
medical services. In other words, the NHI has medical information on around 50
million South Koreans. We hope this example will be useful for readers to conduct
cost-of-illness studies.
3.1 Study design and cost components
The present example adopts the prevalence-based approach, because it is
important to take into account both new and existing patients suffering from
allergic diseases during certain periods. As well, this example employs the human
capital approach as the value assessment method, because it clearly quantifies losses







Portion of cost confirmed by the HIRA and paid
by insurers









Cost of prescription drugs paid by insurers
Prescription
copayment
Cost of prescription drugs paid by patients
OTC drug
cost




Cost of transportation Cost of traveling to and from medical
institutions
Cost of caregiving Cost of hiring professional caregivers or




Outpatients Loss of working hours due to visiting medical
institutions as outpatients
Hospitalized patients Loss of working hours due to hospitalization
Premature deaths Losses of productivity due to death of patients
Intangible Declines in quality of life, psychological
suffering, etc.
Cost associated with declining quality of life and
psychological suffering
Table 4.
Cost components and definitions.
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of productivity due to illness based on patientsʼ income levels. Moreover, it is better
suited to ensuring the objectivity of analysis results, as it excludes the researcherʼs
bias. As for perspective, this study adopts the societal perspective and estimates
both the direct costs paid by the insurer and patients and society-wide losses of
productivity.
As the purpose of this study is to estimate the entire scope of the socioeconomic
costs generated by allergic diseases in South Korea, this study estimates both the
direct and indirect costs. The direct costs are divided into healthcare and non-
healthcare costs, as in previous studies that adopted the societal perspective. The
indirect costs involve losses of productivity. More specifically, the direct healthcare
costs include the costs incurred by outpatients and hospitalized patients,
encompassing covered costs paid by insurer, copayments made by patients, non-
covered costs, and prescription costs. The direct non-healthcare costs involve all
expenses associated with visiting medical institutions, whether as outpatients or
hospitalized patients, and receiving services for the treatment and management of
allergic diseases, including the costs of transportation and caregiving. The indirect
costs, or losses of productivity, are estimated by defining the number of hospitali-
zation days as the number of working days lost and the amounts of time spent for
outpatient visits, as losses of working time. The losses of future income due to the
premature deaths are estimated for patients aged 15–69 (patients outside of this age
bracket are excluded, as, in accordance with the law, they constitute the non-
working-age population). Due to the absence of objective data, however, intangible
costs are not estimated in this example. The figure below summarizes the compo-
nents of costs estimated in this study (Table 5).
3.2 Data source and case definition
To analyze the socioeconomic costs due to allergic diseases in South Korea, this
study used the 2014 National Patient Sample (NPS) derived from NHI data that
were collected by the HIRA. In South Korea, almost all citizens (98% or higher) are
compulsory subscribers to the NHI scheme, which is a type of social insurance, and
all medical institutions are required to submit claim data to the HIRA to charge the
bill for the medical services they provided when patients visited the medical insti-
tution. Consequently, the HIRA has medical information on around 50 million
South Koreans. The NPS is the data of patients sampled from the large amount of
claim data held by the HIRA, and it is an abridged version of claim data that contain
1-year information regarding medical treatments and prescriptions of the sampled
patients. The data contain the information of about 1.4 million patients, who repre-
sent a sample of 3% of all patients.




Non-healthcare costs Cost of transportation
Cost of caregiving
Indirect costs Losses of productivity
Table 5.
Components of estimated costs in this example.
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The NHI data is administrative data, and the prevalence rate is influenced by the
case definition of disease. In other words, prevalence rates can vary dramatically
depending on how the cases are defined. Most of previous studies that made use of
administrative data including NHI data generally used primary diagnoses to esti-
mate prevalence rates. This approach, however, carries the risk of either
underestimating or overestimating the prevalence rates. This study therefore
applied more rigorous criteria in defining prevalence. First, it identified and
extracted patients whose primary and secondary diagnoses were indicated using the
ICD-10 codes for allergic diseases. Of these patients, this study identified those who
had been hospitalized or made at least two outpatient visits each for allergic diseases
and had been prescribed drugs commonly used to treat allergic diseases (as indi-
cated in their insurance billing records), such as nedocromil sodium, oral steroids,
ventolin, and so on. Only patients meeting these rigorous criteria were admitted
into this study as patients.
3.3 Estimation methods
The sources of data for each component of the costs estimated in this study—
including direct and indirect costs—are as follows.
3.3.1 Direct costs
Direct costs refer to the amounts of spending directly related to illness and are
divided into healthcare and non-healthcare costs.
Direct healthcare costs are the costs of preventing, treating, or managing ill-
nesses by using medical institutions and include the costs of outpatient services,
hospitalization, and medications (prescriptions). The majority of existing studies
that estimate direct healthcare costs rely on administrative and official statistics for
their estimations. As there is little controversy over the use of administrative and
official statistics in estimating the direct healthcare costs of illness, this study, also,
uses the NHI data to estimate the direct healthcare costs of allergic diseases.
Depending on who pays them, direct healthcare costs can be further broken down
into covered costs paid by insurer, copayments made by patients, and non-covered
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where DHC = Direct healthcare costs, s = Sex, y = Age, E = Costs, i = Hospitalized
patients, o = Outpatients, α = Non-covered cost ratio (hospitalized patients),
β = Non-covered cost ratio (outpatients).
The direct non-healthcare costs are the costs of transportation and caregiving
incurred by patients in seeking and receiving the services of medical institutions.
This study draws upon the national official statistics data on transportation costs.
This data include information on the costs of one-way transportation paid by out-
patients and hospitalized patients and estimate the final costs of transportation
based on the assumption that some patients would be accompanied by their care-
givers. The costs of one-way trips were multiplied by the price-adjusted index and
used to estimate the total costs of round-trip transportation. As for the cost of
caregiving, this study used the average daily cost of hiring a caregiver, as suggested
by the caregivers association. Defining the cost of caregiving as the opportunity cost
of caregiversʼ time during patientsʼ hospitalization, this study applied the average
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daily wage for caregivers as the unit cost of caregiving. This unit cost was then
multiplied by the number of hospitalization days. The cost of caregiving was also
estimated for outpatient visits based on the assumption that each outpatient visit
takes up one-third of the caregiverʼs daily working hours. The formula used to
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where NHC = Direct non-healthcare costs, s = Sex, y = Age, N = Number of
visits, i = Inpatients, o = Outpatients, Ct = Cost of transportation, L = Length of stay,
Cc = Cost of caregiving.
3.3.2 Indirect costs
Indirect costs do not represent actual financial costs paid but the losses of labor
and productivity due to illnesses. The indirect costs represent the amounts of
working time lost in order to visit and use the services of medical institutions, the
loss of future income due to the premature death of patients, and the opportunity
cost of caregiving. The opportunity costs so incurred include not only the amount of
working time lost but also the amount of leisure time lost. This study draws upon
the employment and labor statistics provided by the government in order to esti-
mate the indirect costs. These statistics are part of the official employment and
labor statistics that provide information on the average daily and monthly wages,
total working hours, and employment rates by sex and age.
The losses of labor (productivity) due to the need for treatment and recovery
and losses of future income due to premature death were estimated in the following
manner. First, loss of labor can be understood as the opportunity cost of labor
incurred by spending time hospitalized or making outpatient visits to medical
institutions instead of working. These opportunity costs were thus estimated for the
working-age population (ages 15–69). In the case of hospitalized patients, loss of
productivity was found by multiplying the daily average wage for each age group by
the number of hospitalization days. For outpatients, the daily average wage for each
age group was multiplied by the number of outpatient visits made, and the result
was divided by 3 (based on the assumption that outpatient visits took up one-third
of each patientʼs daily working hours). The formula used to estimate the losses of











where PL = Productivity loss, s = Sex, y = Year, N = Number of hospitalization
days (visits), i = Inpatients, o = Outpatients, W = Average wage, E = Employment
rate.
The loss of future income due to the premature death of patients represents the
decrease in expected income that individuals could have earned had they lived to
their full life expectancy. To estimate this loss, this study relied upon the raw data
for the official statistics on causes of death provided by the government to identify
the number of deaths by sex and age and then applied the death rate to the average
monthly wage and number of working days for each age group. The loss of future
income was again estimated for the working-age population (ages 15–69) only,
applying the employment rate of each age group. In order to convert the estimated
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loss of future income into a present value, a discount rate was applied, and the
sensitivity to changes in the discount rate was checked by applying additional
discount rates. The formula used to estimate the loss of future income due to












where LFI = Loss of future income, s = Sex, y = Age, k = 1,2,… , n (where “n”
represents the difference between the life expectancy and actual average age at
death for each age cohort), t = Age at death, r = Discount rate, Nsy = Number of
premature deaths associated with allergic diseases by sex and age, Ysy(t + k) =
Annual average income at t + k by sex and age, Psy(t + k) = Employment rate at
t + k by sex and age.
4. Conclusions
The COI study measures socioeconomic losses from certain diseases in a coun-
try. Therefore, it can provide basic information and evidence that is very important
for policy prioritization and resource allocation. For these reasons, many countries
are using the COI study to establish health policies. In particular, the COI study has
the advantage that it is easy to understand not only policymakers but also the
general public by converting national losses from diseases into monetary value.
In this chapter, we reviewed various methodologies and techniques for estimat-
ing the socioeconomic burden of disease. As well, we presented an example of COI
study. We hope that this chapter will help readers better understand and use the
COI study.
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